Title of Invention

NUCLEIC ACID BASE HAVING PERFLUOROALKYL GROUP AND METHOD FOR PRODUCING THE SAME

Abstract Provided is a simple and efficient production process of a nucleobase having a perfluoroalkyl group. A nucleobase (for example, uracils, cytosines, adenines, guanines, hypoxanthines, xanthines, or the like) is reacted with a perfluoroalkyl halide in the presence of a sulfoxide, a peroxide and an iron compound to produce a perfluoroalkyl-substituted nucleobase, which is useful as an intermediate for medical drugs, economically.
Full Text DESCRIPTION
NUCLEOBASE HAVING PERFLUOROALKYL GROUP AND PROCESS FOR
PRODUCING THE SAME
TECHNICAL FIELD
The present invention relates to a process for
producing a nucleobase having a perfluoroalkyl group.
BACKGROUND ART
Nucleobases substituted by a perfluoroalkyl group
are important compounds as medical drugs and
intermediates for medical and agricultural chemicals, and
nucleobases having a trifluoromethyl group are
particularly useful compounds. Therefore, many studies
have been conducted on processes for producing the
trifluoromethyl-substituted nucleobases.
With respect to a method for producing 5-
trifluoromethyl uracil which is important as an
intermediate for an anticancer agent, an antiviral agent,
or the like, for example, Patent Document 1 discloses a
method for producing 5-trifluoromethyl uracil by reacting
5-trifluoromethyl-5,6-dihydrouracil which is obtained by
a reaction of -trifluoromethyl acrylic acid and urea,
with dimethyl sulfoxide and iodine in the presence of
concentrated sulfuric acid as a catalyst. Furthermore,
Patent Document 2 discloses a method of reacting 5-

iodouracils with copper iodide and methyl
fluorosulfonyldifluoroacetate to convert them to a 5-
trifluoromethyluracils. Moreover, Patent Document 3
discloses a method for producing 5-trifluoromethyluracil,
in which thymine is chlorinated with a chlorine gas to
form 2,4-dichloro-5-trichloromethylpyrimidine, and then
fluorinated with anhydrous hydrofluoric acid or antimony
trifluoride in the coexistence with antimony
pentachloride, followed by a treatment with water.
However, these methods have problems that all the methods
include multi-steps and the last method uses anhydrous
hydrofluoric acid and the antimony compound which are
industrially hard to handle. Moreover, Non-patent
Document 1 discloses a method for trifluoromethylating
3',5'-diacetyl-2'-deoxyuridine at the 5-position with
trifluoroacetic acid and xenon difluoride. However, this
method also uses a special reagent and is industrially
hard to employ.
Furthermore, with respect to a method for producing
5-trifluoromethylcytosine, Non-patent Document 2
discloses a method for producing 5-
trifluoromethylcytosine by hydrolyzing 4-amino-2-chloro-
5-trifluoromethylpyrimidine obtained by a reaction of
2,4-dichloro-5-trifluoromethylpyrimidine and liquid
ammonia, and treating it with an ion-exchange resin.
However, this method has a problem of multi-steps
including production of raw materials.

With respect to a method for producing a purine
compound having a trifluoromethyl group, for example,
Non-patent Document 3 discloses a method for producing 8-
trifluoromethyladenine, 2,6-diamino-8-
trifluoromethylpurine and 8-trifluoromethylhypoxanthine
by reacting 4,5-diaminopyrimidines with trifluoroacetic
acid or trifluoroacetic anhydride. Non-patent Document 4
discloses a method for producing 8-trifluoromethylguanine
by reacting 2,4-diamino-5-trifluoroacetamino-6-oxo-l,6-
dihydropyrimidine, which is obtained by a reaction of
2,4,5-triamino-6-oxo-l,6-dihydropyrimidine and
trifluoroacetic acid, with trifluoroacetic anhydride.
However, all of these methods also industrially have a
problem of multi-steps including production of raw
materials.
With respect to direct perfluoroalkylation of these
nucleobases, for example, Patent Document 4 discloses a
method for producing purines having a perfluoroalkyl
group at the 8-position or 2-position by reacting purines
with N,O-bis(trimethylsilyl)trifluoroacetamide in the
presence of pyridine and trimethylchlorosilane as
catalysts and then reacting the resultant with bis
(perfluoroalkyl) peroxide. However, this method has
problems that it uses di(haloacyl) peroxide which is
industrially hard to handle, that it uses a
chlorofluorocarbon solvent and that it forms regioisomers
with the substituent at the different positions.

Furthermore, Non-patent Documents 5 and 6 disclose a
method for producing 8-perfluorobutyluracil, 8-
perfluorobutylhypoxanthine and an 8-
perfluorobutylxanthine salts by the formation of a uracil
anion electrochemically, followed by the reaction with
perfluorobutyl iodide. However, this method has problems
that it uses the electrochemical technique which is
industrially hard to use and that the resulting product
is a salt of a supporting electrolyte.
Non-patent Document 7 discloses a method for
producing 8-trifluoromethylcaffeine by reacting 8-
trifluoromethyltheophylline obtained by a reaction of
5,6-diamino-1,3-dimethyluracil and trifluoroacetic
anhydride, with potassium carbonate and methyl iodide in
N,N-dimethylformamide. However, this method industrially
has a problem of multi-steps including production of raw
materials.
With respect to perfluoroalkylation with a
perfluoroalkyl halide, Non-patent Document 8 discloses a
method for obtaining trifluoromethylnucleosides by
reacting 2',3',5'-tri-O-acetylated iodonucleosides with
copper powder and trifluoromethyl iodide in
hexamethylphosphoric triamide to obtain a 2',3',5'-tri-O-
acetylated trifluoromethylnucleosides, and followed by
deprotecting them. However, this method also has
problems of multi-steps and use of hexamethylphosphoric
triamide which is industrially hard to use.

Moreover, Non-patent Documents 9 and 10 disclose a
process using perfluorobutyl iodide or perfluoropropyl
iodide which is liquid at room temperature, through the
use of dimethyl sulfoxide, hydrogen peroxide and ferric
sulfate. However, substrates are restricted to pyrroles,
indoles and substituted benzenes. Furthermore, there is
no description with respect to trifluoromethylation using
a perfluoroalkyl halide which is gas at room temperature,
for example, trifluoromethyl iodide.
Patent Document 1: JP-A-2001-247551
Patent Document 2: JP-A-11-246590
Patent Document 3: JP-A-6-73023
Non-patent Document 1: Journal of Organic Chemistry, Vol.
53, pp. 4582-4585, in 1988
Non-patent Document 2: Journal of Medicinal Chemistry,
Vol. 13, pp. 151-152, in 1970
Non-patent Document 3: Journal of the American Chemical
Society, Vol. 80, pp. 5744-5752, in 1957
Non-patent Document 4: Justus Libigs Annalen der Chemie,
Vol. 726, pp. 201-215, in 1969
Patent Document 4: JP-A-5-1066
Non-patent Document 5: Tetrahedron Letters, Vol. 33, pp.
7351-7354, in 1992
Non-patent Document 6: Tetrahedron, Vol. 56, pp. 2655-
2664,in 2000
Non-patent Document 7: Journal of Medicinal Chemistry,
Vol. 36, pp. 2639-2644, in 1993

Non-patent Document 8: Journal of the Chemical Society,
Perkin Transaction 1, pp. 2755-2761, in 1980
Non-patent Document 9: Tetrahedron Letters, Vol. 34, No.
23, pp. 3799-3800, in 1993
Non-patent Document 10: Journal of Organic Chemistry,
Vol. 62, pp. 7128-7136, in 1997
DISCLOSURE OF THE INVENTION
OBJECT TO BE ACCOMPLISHED BY THE INVENTION
An object of the present invention is to provide a
simple and efficient process for producing a nucleobase
having a perfluoroalkyl group.
MEANS TO ACCOMPLISH THE OBJECT
In order to accomplish the above object, the
inventors of the present invention have conducted
intensive and extensive studies and as a result, found
that a nucleobase could be perfluoroalkylated in one step
with a perfluoroalkyl halide in the presence of a
sulfoxide, a peroxide and an iron compound, thereby very
simply producing the nucleobase having a perfluoroalkyl
group, so as to accomplish the present invention.
Namely, the present invention has the following
aspects:
1. A process for producing a nucleobase having a
perfluoroalkyl group, the process comprising: carrying
out a reaction of a nucleobase with a perfluoroalkyl

halide represented by the general formula (2)

wherein Rf is a C1-C6 perfluoroalkyl group and X is a
halogen atom, in the presence of a sulfoxide represented
by the general formula (1)

wherein each of R1a and Rlb is a C1-C12 alkyl group or an
optionally substituted phenyl group, a peroxide and an
iron compound.
2. The process according to the above aspect 1, wherein
the reaction is carried out in the presence of an acid.
3. The process according to the above aspect 1 or 2,
wherein the nucleobase are uracils represented by the
general formula (3)

wherein R2 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group or a protecting group for nitrogen, R3
is a hydrogen atom, an optionally substituted C1-C6 alkyl
group, a protecting group for nitrogen, or one of pentose
residues and analogs thereof, and R4 is a hydrogen atom,

an optionally substituted C1-C6 alkyl group, an
optionally substituted C1-C4 alkoxy group, an optionally
substituted amino group, a carboxy group, an optionally
substituted carbamoyl group, or an optionally substituted
C2-C5 alkoxycarbonyl group; cytosines represented by the
general formula (4)

wherein R5 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group, a protecting group for nitrogen, or
one of pentose residues and analogs thereof, R6 is a
hydrogen atom, an optionally substituted C1-C6 alkyl
group, an optionally substituted amino group, a carboxy
group, an optionally substituted carbamoyl group, or an
optionally substituted C2-C5 alkoxycarbonyl group, and
each of R7 and R8 is a hydrogen atom or a protecting
group for nitrogen; adenines represented by the general
formula (5)


wherein R9 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group, a protecting group for nitrogen, or
one of pentose residues and analogs thereof, R10 is a
hydrogen atom, an optionally substituted C1-C6 alkyl
group, an optionally substituted amino group, a carboxy
group, an optionally substituted carbamoyl group, or an
optionally substituted C2-C5 alkoxycarbonyl group, and
each of R11 and R12 is a hydrogen atom or a protecting
group for nitrogen; guanines represented by the general
formula (6)

wherein R13 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group or a protecting group for nitrogen, R14
is a hydrogen atom, an optionally substituted C1-C6 alkyl
group, a protecting group for nitrogen, or one of pentose
residues and analogs thereof, and each of R15 and R16 is a
hydrogen atom or a protecting group for nitrogen; a

hypoxanthine compound represented by the general formula
(7)

wherein R17 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group or a protecting group for nitrogen, and
R18 is a hydrogen atom, an optionally substituted C1-C6
alkyl group, a protecting group for nitrogen, or one of
pentose residues and analogs thereof; or xanthines
represented by the general formula (8)

wherein R19 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group or a protecting group for nitrogen, R20
is a hydrogen atom, an optionally substituted C1-C6 alkyl
group, a protecting group for nitrogen, or one of pentose
residues and analogs thereof, and R21 is a hydrogen atom,
an optionally substituted C1-C6 alkyl group or a
protecting group for nitrogen.
4. The process according to the above aspect 3, wherein
the nucleobase are uracils represented by the general

formula (3)

wherein R2, R3 and R4 are the same as those defined above.
5. The process according to any one of the above aspects
1 to 4, wherein X is iodine or bromine.
6. The process according to any one of the above aspects
1 to 5, wherein Rf is a trifluoromethyl group or a
perfluoroethyl group.
7. The process according to any one of the above aspects
1 to 6, wherein the iron compound is ferric sulfate,
ammonium ferric sulfate, ferric tetrafluoroborate, ferric
chloride, ferric bromide, ferric iodide, ferric acetate,
ferric oxalate, bis(acetylacetonato)iron, ferrocene,
bis (η5-pentamethylcyclopentadienyl) iron or an iron
powder.
8. The process according to the above aspect 7, wherein
the iron compound is ferric sulfate, ammonium ferric
sulfate, ferric tetrafluoroborate, ferrocene or an iron
powder.
9. The process according to any one of the above aspects
1 to 8, wherein the peroxide is hydrogen peroxide, a
hydrogen peroxide-urea composite, tert-butyl peroxide or
peroxyacetic acid.

10. The process according to the above aspect 9, wherein
the peroxide is hydrogen peroxide or a hydrogen peroxide-
urea composite.
11. The process according to any one of the above
aspects 2 to 10, wherein the acid is sulfuric acid,
hydrochloric acid, hydrogen bromide, hydrogen iodide,
nitric acid, phosphoric acid, hexafluorophosphoric acid,
tetrafluoroboric acid, formic acid, acetic acid,
propionic acid, oxalic acid, p-toluenesulfonic acid,
trifluoromethanesulfonic acid or trifluoroacetic acid.
12. The process according to the above aspect 11,
wherein the acid is sulfuric acid, tetrafluoroboric acid
or trifluoromethanesulfonic acid.
13. The process according to any one of the above
aspects 1 to 12, wherein each of Rla and Rlb is a methyl
group, a butyl group or a phenyl group.
14. The process according to any one of the above
aspects 1 to 13, wherein a temperature of the reaction is
from 20 to 100°C.
15. The process according to any one of the above
aspects 1 to 14, wherein a pressure of the reaction is
from the atmospheric pressure (0.1 MPa) to 1.0 MPa.
16. 5-Perfluoroalkyluracils represented by the general
formula (9)


wherein Rf is a C1-C6 perfluoroalkyl group, each of R22
and R23 is a hydrogen atom or an optionally substituted
C1-C6 alkyl group, and R24 is an optionally substituted
C1-C6 alkyl group, an optionally substituted amino group
or an optionally substituted C2-C5 alkoxycarbonyl group,
provided that in a case where each of R22 and R23 is a
hydrogen atom, R24 is an optionally substituted C2-C5
alkoxycarbonyl group.
17. 8-Perfluoroalkylxanthines represented by the general
formula (10)

wherein Rf is a C1-C6 perfluoroalkyl group, and each of
R25, R26 and R27 is a hydrogen atom or an optionally
substituted C1-C6 alkyl group, provided that R25, R26 and
R27 are not a hydrogen atom all together.
EFFECTS OF THE INVENTION
The present invention realized high-yield and

economical production of the nucleobase having a
perfluoroalkyl group, which is a useful compound as a
medical drug or an intermediate for medical and
agricultural chemicals.
BEST MODE FOR CARRYING OUT THE INVENTION
Now, the present invention will be described in
further detail.
Each of a nucleobase as a raw material and a
nucleobase having a perfluoroalkyl group as a product in
the present invention may be a mixture of tautomers such
as a keto-form and an enol-form, and the present
invention includes such tautomers. They are described in
the keto-form in the description and claims of the
present application for the sake of convenience.
Specific examples of the C1-C12 alkyl group denoted
by each of Rla and Rlb include a methyl group, an ethyl
group, a propyl group, an isopropyl group, a cyclopropyl
group, a butyl group, an isobutyl group, a sec-butyl
group, a tert-butyl group, a cyclobutyl group, a
cyclopropylmethyl group, a dodecyl group, and so on.
Specific examples of the optionally substituted phenyl
group denoted by each of Rla and Rlb include a phenyl
group, a p-tolyl group, a m-tolyl group, an o-tolyl
group, and so on. Each of Rla and Rlb is preferably a
methyl group, a butyl group, a dodecyl group, a phenyl
group or a p-tolyl group, and more preferably a methyl

group, a butyl group or a phenyl group in terms of a good
yield.
Specific examples of the C1-C6 perfluoroalkyl group
denoted by Rf include a trifluoromethyl group, a
perfluoroethyl group, a perfluoropropyl group, a
perfluoroisopropyl group, a perfluorocyclopropyl group, a
perfluorobutyl group, a perfluoroisobutyl group, a
perfluoro-sec-butyl group, a perfluoro-tert-butyl group,
a perfluorocyclobutyl group, a perfluorocyclopropylmethyl
group, a perfluoropentyl group, a perfluoro-1,1-
dimethylpropyl group, a perfluoro-1,2-dimethylpropyl
group, a perfluoroneopentyl group, a perfluoro-1-
methylbutyl group, a perfluoro-2-methylbutyl group, a
perfluoro-3-methylbutyl group, a
perfluorocyclobutylmethyl group, a perfluoro-2-
cyclopropylethyl group, a perfluorocyclopentyl group, a
perfluorohexyl group, a perfluoro-1-methylpentyl group, a
perfluoro-2-methylpentyl group, a perfluoro-3-
methylpentyl group, a perfluoroisohexyl group, a
perfluoro-1,1-dimethylbutyl group, a perfluoro-1,2-
dimethylbutyl group, a perfluoro-2,2-dimethylbutyl group,
a perfluoro-1,3-dimethylbutyl group, a perfluoro-2,3-
dimethylbutyl group, a perfluoro-3,3-dimethylbutyl group,
a perfluoro-1-ethylbutyl group, a perfluoro-2-ethylbutyl
group, a perfluoro-1,1,2-trimethylpropyl group, a
perfluoro-1,2,2-trimethylpropyl group, a perfluoro-1-
ethyl-1-methylpropyl group, a perfluoro-1-ethyl-2-

methylpropyl group, a perfluorocyclohexyl group, and so
on.
In terms of good performance as a medical drug and a
good yield, Rf is preferably a trifluoromethyl group, a
perfluoroethyl group, a perfluoropropyl group, a
perfluoroisopropyl group, a perfluorobutyl group, a
perfluoroisobutyl group, a perfluoro-sec-butyl group, a
perfluoro-tert-butyl group or a perfluorohexyl group,
more preferably a trifluoromethyl group or a
perfluoroethyl group.
X is a halogen atom and specific examples thereof
include a fluorine atom, a chlorine atom, a bromine atom
and an iodine atom. In terms of a good yield, X is
preferably an iodine atom or a bromine atom, and more
preferably an iodine atom.
Examples of the nucleobase in the present invention
include uracils, pseudouracils, thymines, cytosines,
adenines, guanines, hypoxanthines and xanthines, whose
basic skeletons are (N-1) to (N-8), respectively, as
shown in Table 1.

TABLE 1

Of them the nucleobase are preferably uracils,
cytosines, adenines, guanines, hypoxanthines or xanthines
represented by the general formulae (3) to (8) ,
respectively, and particularly preferably uracils
represented by the general formula (3) among others in
terms of good performance as a medical drug.




wherein R2 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group or a protecting group for nitrogen, R3
is a hydrogen atom, an optionally substituted C1-C6 alkyl
group, a protecting group for nitrogen, or one of pentose
residues and analogs thereof, R4 is a hydrogen atom, an
optionally substituted C1-C6 alkyl group, an optionally
substituted C1-C4 alkoxy group, an optionally substituted
amino group, a carboxy group, an optionally substituted
carbamoyl group, or an optionally substituted C2-C5
alkoxycarbonyl group, R5 is a hydrogen atom, an
optionally substituted C1-C6 alkyl group, a protecting
group for nitrogen, or one of pentose residues and
analogs thereof, R6 is a hydrogen atom, an optionally
substituted C1-C6 alkyl group, an optionally substituted
amino group, a carboxy group, an optionally substituted
carbamoyl group, or an optionally substituted C2-C5
alkoxycarbonyl group, each of R7 and R8 is a hydrogen
atom or a protecting group for nitrogen, R9 is a hydrogen
atom, an optionally substituted C1-C6 alkyl group, a
protecting group for nitrogen, or one of pentose residues
and analogs thereof, R10 is a hydrogen atom, an
optionally substituted C1-C6 alkyl group, an optionally
substituted amino group, a carboxy group, an optionally
substituted carbamoyl group, or an optionally substituted
C2-C5 alkoxycarbonyl group, each of R11 and R12 is a
hydrogen atom or a protecting group for nitrogen, R13 is
a hydrogen atom, an optionally substituted C1-C6 alkyl

group or a protecting group for nitrogen, R14 is a
hydrogen atom, an optionally substituted C1-C6 alkyl
group, a protecting group for nitrogen, or one of pentose
residues and analogs thereof, each of R15 and R16 is a
hydrogen atom or a protecting group for nitrogen, R17 is
a hydrogen atom, an optionally substituted C1-C6 alkyl
group or a protecting group for nitrogen, R18 is a
hydrogen atom, an optionally substituted C1-C6 alkyl
group, a protecting group for nitrogen, or one of pentose
residues and analogs thereof, R19 is a hydrogen atom, an
optionally substituted C1-C6 alkyl group or a protecting
group for nitrogen, R20 is a hydrogen atom, an optionally
substituted C1-C6 alkyl group, a protecting group for
nitrogen, or one of pentose residues and analogs thereof,
and R21 is a hydrogen atom, an optionally substituted C1-
C6 alkyl group or a protecting group for nitrogen.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by each of R2 and R3 in the
general formula (3) include a methyl group, an ethyl
group, a propyl group, an isopropyl group, a cyclopropyl
group, a butyl group, an isobutyl group, a sec-butyl
group, a tert-butyl group, a cyclobutyl group, a
cyclopropylmethyl group, a pentyl group, a neopentyl
group, a hexyl group, a cyclohexyl group, and so on.
Furthermore, each of these alkyl groups may be
substituted by a halogen atom and specific examples of
the substituted alkyl group include a chloromethyl group,

a 2-chloroethyl group, a 3-chloropropyl group, a
difluoromethyl group, a 3-fluoropropyl group, a
trifluoromethyl group, a 2-fluoroethyl group, a 2,2,2-
trifluoroethyl group, a 2,2,2-trichloroethyl group, and
so on.
Specific examples of the protecting group for
nitrogen denoted by each of R2 and R3 include an acetyl
group, a propionyl group, a pivaloyl group, a propargyl
group, a benzoyl group, a p-phenylbenzoyl group, a benzyl
group, a p-methoxybenzyl group, a trityl group, a 4,4'-
dimethoxytrityl group, a methoxyethoxymethyl group, a
phenyloxycarbonyl group, a benzyloxycarbonyl group, a
tert-butoxycarbonyl group, a 9-fluorenylmethoxycarbonyl
group, an allyl group, a p-methoxyphenyl group, a
trifluoroacetyl group, a methoxymethyl group, a 2-
(trimethylsilyl)ethoxymethyl group, an allyloxycarbonyl
group, a trichloroethoxycarbonyl group, and so on.
R2 is preferably a hydrogen atom or a methyl group in
terms of a good yield.
Specific examples of the pentose residues and
analogs thereof denoted by R3 include (P-1) to (P-401)
shown in Tables 2 to 16. It is noted that in (P-l) to
(P-401) a filled circle is a nitrogen atom to which the
nucleobase bonds, Me is a methyl group, Et is an ethyl
group, Pr is a propyl group, 1Pr is an isopropyl group,
Bu is a butyl group, tBu is a tert-butyl group, Ph is a
phenyl group, TMS is a trimethylsilyl group, TBDPS is a

tert-butyldiphenylsilyl group and Ts is a tosyl group.
In addition, a free hydroxyl group in the pentose
residue may be protected with a protecting group
generally used such as a benzoyl group, a p-chlorobenzoyl
group, a toluyl group, a benzyl group, a tert-
butylcarbonyl group, a tert-butyldimethylsilyl group, an
acetyl group, a mesyl group, a benzyloxycarbonyl group, a
tert-butyldiphenylsilyl group, a trimethylsilyl group, a
tosyl group, a tert-butylcarbonyl group, a p-
methoxyphenylcarbonyl group, a p-monomethoxytrityl group,
a di(p-methoxy)trityl group, a p-chlorophenylcarbonyl
group, a m-trifluoromethylcarbonyl group, a pivaloyl
group, a (9-fluorenyl)methoxycarbonyl group, a (biphenyl-
4-yl) carbonyl group, a fortnyl group, a (2-
naphthyl)carbonyl group, a tert-butyldimethylsilyl group,
a triisopropylsilyl group, a tripropylsilyl group, a
triphenylmethyl group, a butylcarbonyl group, an
ethylcarbonyl group, a propylcarbonyl group, a
nonylcarbonyl group or a p-methoxyphenyl group.
In addition, when the hydroxyl groups exist both at
the 2'-position and 3'-position, they may be protected
together by an isopropylidene group or the like to form a
ring. Furthermore, a free amino group may be protected
with a protecting group generally used such as a
trifluoromethylcarbonyl group, a 2,4-dinitrophenyl group,
a tosyl group, an acetyl group, a benzyloxycarbonyl
group, a triphenylmethyl group, a benzoyl group, a benzyl

group, an adamantylcarbonyl group, a butylcarbonyl group,
a phthaloyl group or a tetrabromophthaloyl group.
Moreover, a free mercapto group may be protected with a
protecting group generally used such as a 2,4,6-
triisopropylphenyl group, a benzoyl group, a benzyl group
or an acetyl group.

TABLE 2
























TABLE 16

R3 is preferably a hydrogen atom, a methyl group, (P-
34), (P-35), (P-75), (P-100), (P-101), (P-123), (P-152),
(P-153), (P-314) or (P-315) in terms of usefulness as a
medical or agricultural chemical or an intermediate
thereof.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by R4 in the general formula (3)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2.
Specific examples of the optionally substituted C1-
C4 alkoxy group include a methoxy group, an ethoxy group,
a propoxy group, an isopropyloxy group, a cyclopropyloxy
group, a butoxy group, an isobutyloxy group, a sec-
butyloxy group, a tert-butyloxy group, a cyclobutyloxy
group, a cyclopropylmethyloxy group and so on.
Furthermore each of these alkoxy groups may be
substituted by a halogen atom, and specific examples
thereof include a chloromethoxy group, a 2-chloroethoxy

group, a 3-chloropropoxy group, a difluoromethoxy group,
a 3-fluoropropoxy group, a trifluoromethoxy group, a 2-
fluoroethoxy group, a 2,2,2-trifluoroethoxy group, a
2,2,2-trichloroethoxy group, and so on.
Examples of the optionally substituted amino group
denoted by R4 include an amino group which may be
substituted by a C1-C4 alkyl group and specific examples
thereof include an amino group, a methylamino group, an
ethylamino group, a propylamino group, an isopropylamino
group, a butylamino group, an isobutylamino group, a sec-
butylamino group, a tert-butylamino group, an N,N-
dimethylamino group, an N,N-diethylamino group, an N,N-
dipropylamino group, an N,N-diisopropylamino group, an
N,N-dibutylamino group, an N,N-diisobutylamino group, an
N,N-di-sec-butylamino group, an N,N-di-tert-butylamino
group, and so on.
Furthermore, the amino group may be substituted by a
protecting group for nitrogen, and specific examples of
the substituted amino group include an acetylamino group,
a propionylamino group, a pivaloylamino group, a
propargylamino group, a benzoylamino group, a p-
phenylbenzoylamino group, a benzylamino group, a p-
methoxybenzylamino group, a tritylamino group, a 4,4'-
dimethoxytritylamino group, a methoxyethoxymethylamino
group, a phenyloxycarbonylamino group, a
benzyloxycarbonylamino group, a tert-butoxycarbonylamino
group, a 9-fluorenylmethoxycarbonylamino group, an

allylamino group, a p-methoxyphenylamino group, a
trifluoroacetylamino group, a methoxymethylamino group, a
2-(trimethylsilyl)ethoxymethylamino group, an
allyloxycarbonylamino group, a
trichloroethoxycarbonylamino group, and so on.
An example of the optically substituted carbamoyl
group denoted by R4 includes a carbamoyl group which may
be substituted by a C1-C4 alkyl group on the nitrogen
atom, and specific examples thereof include a carbamoyl
group, an N-methylcarbamoyl group, an N-ethylcarbamoyl
group, an N-propylcarbamoyl group, an N-
isopropylcarbamoyl group, an N-butylcarbamoyl group, an
N,N-dimethylcarbamoyl group, an N,N-diethylcarbamoyl
group, an N,N-dipropylcarbamoyl group, an N,N-
diisopropylcarbamoyl group, an N,N-dibutylcarbamoyl
group, and so on.
Specific examples of the optionally substituted C2-
C5 alkoxycarbonyl group denoted by R4 include a
methoxycarbonyl group, an ethoxycarbonyl group, a
propoxycarbonyl group, an isopropyloxycarbonyl group, a
butyloxycarbonyl group, an isobutyloxycarbonyl group, a
sec-butyloxycarbonyl group, a tert-butyloxycarbonyl group
and so on. Furthermore, each of these alkoxycarbonyl
groups may be substituted by a halogen atom, and specific
examples of the substituted alkoxycarbonyl group include
a 2-chloroethoxycarbonyl group, a 3-
chloropropyloxycarbonyl group, a difluoromethoxycarbonyl

group, a 3-fluoropropyloxycarbonyl group, a
trifluoromethoxycarbonyl group, a 2-fluoroethoxycarbonyl
group, a 2,2,2-trifluroethoxycarbonyl group, a 2,2,2-
trichloroethoxycarbonyl group, and so on.
R4 is preferably a hydrogen atom, a 2-chloroethyl
group, an amino group, a tert-butoxycarbonylamino group
or a carboxy group in terms of a good yield.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by R5 in the general formula (4)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2. Specific examples of
the protecting group for nitrogen denoted by R5 include
the protecting groups for nitrogen described in the
description of R2. Specific examples of the pentose
residues and analogs thereof denoted by R5 include (P-1)
to (P-401) described in the description of R3. R5 is
preferably a hydrogen atom, a methyl group, (P-34), (P-
35), (P-75), (P-100), (P-101), (P-123), (P-152), (P-153),
(P-314) or (P-315) in terms of usefulness as a medical or
agricultural chemical or an intermediate thereof.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by R6 in the general formula (4)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2. Specific examples of
the optionally substituted amino group denoted by R6
include the optionally substituted amino groups described
in the description of R4. Specific examples of the

optionally substituted carbamoyl group denoted by R6
include the optionally substituted carbamoyl groups
described in the description of R4. Specific examples of
the optionally substituted C2-C5 alkoxycarbonyl group
denoted by R6 include the optionally substituted C2-C5
alkoxycarbonyl groups described in the description of R4.
R6 is preferably a hydrogen atom, a 2-chloroethyl group,
an amino group, a tert-butoxycarbonylamino group or a
carboxy group in terms of a good yield.
Specific examples of the protecting group for
nitrogen denoted by each of R7 and R8 in the general
formula (4) include the protecting groups for nitrogen
described in the description of R2. Each of R7 and R8 is
preferably a hydrogen atom or an acetyl group in terms of
a good yield.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by R9 in the general formula (5)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2. Specific examples of
the protecting group for nitrogen denoted by R9 include
the protecting groups for nitrogen described in the
description of R2. Specific examples of the pentose
residues and analogs thereof denoted by R9 include (P-1)
to (P-401) described in the description of R3. R9 is
preferably a hydrogen atom, a methyl group, (P-34), (P-
35), (P-75) , (P-100) , (P-101), (P-123), (P-152), (P-153),
(P-314) or (P-315) in terms of usefulness as a medical or

agricultural chemical or an intermediate thereof.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by R10 in the general formula (5)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2. Specific examples of
the optionally substituted amino group denoted by R10
include the optionally substituted amino groups described
in the description of R4. Specific examples of the
optionally substituted carbamoyl group denoted by R10
include the optionally substituted carbamoyl groups
described in the description of R4. Specific examples of
the optionally substituted C2-C5 alkoxycarbonyl group
denoted by R10 include the optionally substituted C2-C5
alkoxycarbonyl groups described in the description of R4.
R10 is preferably a hydrogen atom, a 2-chloroethyl group,
an amino group, a tert-butoxycarbonylamino group or a
carboxy group in terms of a good yield.
Specific examples of the protecting group for
nitrogen denoted by each of R11 and R12 in the general
formula (5) include the protecting groups for nitrogen
described in the description of R2. Each of R11 and R12 is
preferably a hydrogen atom or an acetyl group in terms of
a good yield.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by R13 in the general formula (6)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2. Specific examples of

the protecting group for nitrogen denoted by R13 include
the protecting groups for nitrogen described in the
description of R2. R13 is preferably a hydrogen atom or a
methyl group in terms of a good yield.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by R14 in the general formula (6)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2. Specific examples of
the protecting group for nitrogen denoted by R14 include
the protecting groups for nitrogen described in the
description of R2. Specific examples of the pentose
residues and analogs thereof denoted by R14 include (P-1)
to (P-401) described in the description of R3. R14 is
preferably a hydrogen atom, a methyl group, (P-34), (P-
35), (P-75), (P-100), (P-101) , (P-123), (P-152), (P-153),
(P-314) or (P-315) in terms of usefulness as a medial
drug or an agricultural chemical or an intermediate
thereof.
Specific examples of the protecting group for
nitrogen denoted by each of R15 and R16 in the general
formula (6) include the protecting group for nitrogen
described in the description of R2. Each of R15 and R16 is
preferably a hydrogen atom or an acetyl group in terms of
a good yield.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by R17 in the general formula (7)
include the optionally substituted C1-C6 alkyl groups

described in the description of R2. Specific examples of
the protecting group for nitrogen denoted by R17 include
the protecting groups for nitrogen described in the
description of R2. R17 is preferably a hydrogen atom or a
methyl group in terms of a good yield.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by R18 in the general formula (7)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2. Specific examples of
the protecting group for nitrogen denoted by R18 include
the protecting groups for nitrogen described in the
description of R2. Specific examples of the pentose
residues and analogs thereof denoted by R18 include (P-1)
to (P-401) described in the description of R3. R18 is
preferably a hydrogen atom, a methyl group, (P-34), (P-
35), (P-75), (P-100), (P-101), (P-123), (P-152), (P-153),
(P-314) or (P-315) in terms of usefulness as a medical or
agricultural chemical or an intermediate thereof.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by R19 in the general formula (8)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2. Specific examples of
the protecting group for nitrogen denoted by R19 include
the protecting groups for nitrogen described in the
description of R2. R19 is preferably a hydrogen atom or a
methyl group in terms of a good yield.
Specific examples of the optionally substituted C1-

C6 alkyl group denoted by R20 in the general formula (8)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2. Specific examples of
the protecting group for nitrogen denoted by R20 include
the protecting groups for nitrogen described in the
description of R2. Specific examples of the pentose
residues and analogs thereof denoted by R20 include (P-1)
to (P-401) described in the description of R3. R20 is
preferably a hydrogen atom, a methyl group, (P-34), (P-
35), (P-75), (P-100) , (P-101) , (P-123), (P-152), (P-153),
(P-314) or (P-315) in terms of usefulness as a medical or
agricultural chemical or an intermediate thereof.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by R21 in the general formula (8)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2. Specific examples of
the protecting group for nitrogen denoted by R21 include
the protecting groups for nitrogen described in the
description of R2. R21 is preferably a hydrogen atom or a
methyl group in terms of a good yield.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by each of R22 or R23 in the
general formula (9) include the optionally substituted
C1-C6 alkyl groups described in the description of R2.
Each of R22 and R23 may be any one of the alkyl groups
described above, and is preferably a methyl group or an
ethyl group in terms of promising physiological activity.

Specific examples of the optionally substituted C1-C6
alkyl group denoted by R24 in the general formula (9)
include the optionally substituted C1-C6 alkyl groups
described in the description of R2. Specific examples of
the optionally substituted amino group denoted by R24
include the optionally substituted amino groups described
in the description of R4. Specific examples of the
optionally substituted C2-C5 alkoxycarbonyl group denoted
by R24 include the optionally substituted C2-C5
alkoxycarbonyl groups described in the description of R4.
R24 is preferably a methyl group, an ethyl group, an
amino group or an amino group substituted by a protecting
group in terms of usefulness as a medical or agricultural
chemical or an intermediate thereof.
Specific examples of the optionally substituted C1-
C6 alkyl group denoted by each of R25, R26 and R27 in the
general formula (10) include the optionally substituted
C1-C6 alkyl groups described in the description of R2.
Each of R25, R26 and R27 is preferably a methyl group or an
ethyl group in terms of promising performance as a
sustained-release preparation.
Next, the production process of the present
invention will be described in detail.
In a case where the uracils of the general formula
(3) are used as a raw material, the production process is
shown in the following [Process-A], and a 5-
perfluoroalkyluracils represented by the general formula

(11) are obtained.
[Process-A]

wherein R2, R3, R4, Rf and X are the same as those
described above.
In [Process-A], the sulfoxides (1) may be used as a
solvent as they are, but it is also possible to use a
solvent which does not adversely affect the reaction.
Specific examples of the solvent include water, N,N-
dimethylformamide, acetic acid, trifluoroacetic acid,
tetrahydrofuran, diethyl ether, ethyl acetate, acetone,
1,4-dioxane, tert-butyl alcohol, ethanol, methanol,
isopropyl alcohol, trifluoroethanol, hexamethylphosphoric
triamide, N-methyl-2-pyrrolidone, N,N,N',N'-
tetramethylurea, N,N'-dimethylpropyleneurea, and so on,
and these may be used in combination properly. The
solvent is preferably water, the sulfoxides (1), or a
solvent mixture of water and the sulfoxides (1) in terms
of a good yield.
The molar ratio of the uracils (3) and the sulfoxide
(1) is preferably from 1:1 to 1:200, and more preferably

from 1:10 to 1:100 in terms of a good yield.
The molar ratio of the uracils (3) and the
perfluoroalkyl halides (2) is preferably from 1:1 to
1:100, and more preferably from 1:1.5 to 1:10 in terms of
a good yield.
Examples of the peroxides include hydrogen peroxide,
a hydrogen peroxide-urea composite, tert-butyl peroxide,
peroxyacetic acid, and so on, and these may be used in
combination properly. The peroxide is preferably
hydrogen peroxide or a hydrogen peroxide-urea composite
in terms of a good yield.
Hydrogen peroxide may be used after diluting it with
water. On this occasion, the concentration can be from 3
to 70% by weight, but commercially available 35% by
weight hydrogen peroxide may be used as it is. It is
more preferable to dilute hydrogen peroxide with water to
from 10 to 3 0% by weight in terms of a good yield and
safety.
The molar ratio of the uracils (3) and the peroxides
is preferably from 1:0.1 to 1:10, and more preferably
from 1:1.5 to 1:3 in terms of a good yield.
The iron compound is preferably an iron(II) salt in
terms of a good yield and examples thereof include
inorganic acid salts such as ferric sulfate, ammonium
ferric sulfate, ferric tetrafluoroborate, ferric chloride,
ferric bromide and ferric iodide, and organometallic
compounds such as ferric acetate, ferric oxalate,

bis(acetylacetonato)iron, ferrocene, and bis(n5-
pentamethylcyclopentadienyl)iron, and these may be used
in combination properly. In addition, an iron powder, an
iron(O) compound or an iron(I) salt may be used in
combination with an oxidizing reagent such as a peroxide,
so as to generate an iron(II) salt in the system. On
this occasion, hydrogen peroxide used for the reaction
may also be used as the oxidizing reagent as it is. The
iron compound is preferably ferric sulfate, ammonium
ferric sulfate, ferric tetrafluoroborate, ferrocene or an
iron powder in terms of a good yield.
These iron compounds may be used in a solid state as
they are, but they may also be used in the form of a
solution. When they are used in the form of the solution,
a solvent to be used may be any one of the sulfoxides (1)
and the solvents as described above, and water is
preferable among them. On this occasion, the
concentration of the iron compound solution is preferably
from 0.1 to 10 mol/1, and more preferably from 0.5 to 5
mol/1 in terms of a good yield.
The molar ratio of the uracils (3) and the iron
compounds is preferably from 1:0.01 to 1:10, and more
preferably from 1:0.1 to 1:1 in terms of a good yield.
The reaction can be carried out at a temperature
optionally selected from the range of from 20 to 100°C.
The temperature is preferably from 20 to 70°C in terms of
a good yield.

In the case where the reaction is carried out in a
closed system, the reaction can be carried out under a
pressure optionally selected from the range of from the
atmospheric pressure (0.1 MPa) to 1.0 MPa, and the
reaction sufficiently proceeds even under the atmospheric
pressure. Furthermore, an atmosphere in the reaction may
be an inert gas such as argon or nitrogen, but the
reaction sufficiently proceeds even in the atmosphere of
air.
When the perfluoroalkyl halides of the general
formula (2) are gas at room temperature, they may be used
in a gaseous state as they are. On this occasion, they
may be used as a gas mixture after diluting them with a
gas such as argon, nitrogen, air, helium or oxygen,
wherein a molar fraction of the perfluoroalkyl halides
(2) are from 1 to 100%. In the case where the reaction
is carried out in a closed system, the perfluoroalkyl
halides (2) or the gas mixture thereof may be used as a
reaction atmosphere. On this occasion, the pressure can
be one optionally selected from the range of from the
atmospheric pressure (0.1 MPa) to 1.0 MPa, but the
reaction sufficiently proceeds even under the atmospheric
pressure. On the other hand, the perfluoroalkyl halides
(2) or the gas mixture thereof may be introduced by
bubbling into a reaction solution in an open system. On
this occasion, the introduction rate of the
perfluoroalkyl halides (2) or the gas mixture thereof may

be selected from the range of from 1 to 200 ml/min though
it depends on a scale of the reaction, an amount of the
catalyst, a temperature of the reaction, and a molar
fraction of the perfluoroalkyl halides (2) in the gas
mixture.
According to the process of the present invention, a
yield of the desired product can be improved by addition
of an acid. Examples of the acid include inorganic acids
such as sulfuric acid, hydrochloric acid, hydrogen
bromide, hydrogen iodide, nitric acid, phosphoric acid,
hexafluorophosphoric acid and tetrafluoroboric acid, and
organic acids such as formic acid, acetic acid, propionic
acid, oxalic acid, p-toluenesulfonic acid,
trifluoromethanesulfonic acid and trifluoroacetic acid.
These may be used in combination properly. It is
preferable to use sulfuric acid, tetrafluoroboric acid or
trifluoromethanesulfonic acid in terms of a good yield.
In addition, an acid salt of sulfuric acid may also
be used. Examples of the acid salt include
tetramethylammonium hydrogen sulfate, tetraethylammonium
hydrogen sulfate, tetrabutylammonium hydrogen sulfate,
tetraphenylphosphonium hydrogen sulfate, and so on.
These acids may be used after diluting them. A
solvent in that case may be selected from the sulfoxides
(1) and the solvents as described above, and water, the
sulfoxide compound (1) or a solvent mixture of water and
the sulfoxide compound (1) is preferable among them.

The molar ratio of the uracils (3) and the acids is
preferably from 1:0.001 to 1:5, and more preferably from
1:0.01 to 1:2 in terms of a good yield.
There are no particular restrictions on a method for
isolating the desired product from the solution after the
reaction, and the desired product can be obtained by one
of the methods generally used such as solvent extraction,
column chromatography, preparative thin-layer
chromatography, preparative liquid chromatography,
recrystallization and sublimation.
In a case where the cytosines of the general formula
(4) are used as a raw material, the production process is
shown in the following [Process-B], and a 5-
perfluoroalkylcytosines represented by the general
formula (12) are obtained.
[Process-B]

wherein R5, R6, R7, R8, Rf and X are the same as those
described above.
In [Process-B], the sulfoxides (1) may be used as a
solvent as they are, but it is also possible to use a

solvent which does not adversely affect the reaction.
Specific examples of the solvent include water, N,N-
dimethylformamide, acetic acid, trifluoroacetic acid,
tetrahydrofuran, diethyl ether, ethyl acetate, acetone,
1,4-dioxane, tert-butyl alcohol, ethanol, methanol,
isopropyl alcohol, trifluoroethanol, hexamethylphosphoric
triamide, N-methyl-2-pyrrolidone, N,N,N',N'-
tetramethylurea, N,N'-dimethylpropyleneurea, and so on,
and these may be used in combination properly. The
solvent is preferably water, the sulfoxides (1) or a
solvent mixture of water and the sulfoxides (1) in terms
of a good yield.
The molar ratio of the cytosines (4) and the
sulfoxides (1) is preferably from 1:1 to 1:200, and more
preferably from 1:10 to 1:100 in terms of a good yield.
The molar ratio of the cytosines (4) and the
perfluoroalkyl halides (2) is preferably from 1:1 to
1:100, and more preferably from 1:1.5 to 1:10 in terms of
a good yield.
Examples of the peroxides include hydrogen peroxide,
a hydrogen peroxide-urea composite, tert-butyl peroxide,
peroxyacetic acid, and so on, and these may be used in
combination properly. The peroxide is preferably
hydrogen peroxide in terms of a good yield.
Hydrogen peroxide may be used after diluting it with
water. On this occasion, the concentration can be from 3
to 70% by weight, but commercially available 35% by

weight hydrogen peroxide may be used as it is. It is
more preferable to dilute hydrogen peroxide with water to
from 10 to 30% by weight in terms of a good yield and
safety.
The molar ratio of the cytosines (4) and the
peroxides is preferably from 1:0.1 to 1:10, and more
preferably from 1:1.5 to 1:3 in terms of a good yield.
The iron compound is preferably an iron(II) salt in
terms of a good yield and examples thereof include
inorganic acid salts such as ferric sulfate, ammonium
ferric sulfate, ferric tetrafluoroborate, ferric chloride,
ferric bromide and ferric iodide, and organometallic
compounds such as ferric acetate, ferric oxalate,
bis(acetylacetonato)iron(II), ferrocene, and bis(η5-
pentamethylcyclopentadienyl)iron, and these may be used
in combination properly. In addition, an iron powder, an
iron(0) compound or an iron(I) salt may be used in
combination with an oxidizing reagent such as a peroxide,
so as to generate an iron(II) salt in the system. On
this occasion, hydrogen peroxide used for the reaction
may also be used as the oxidizing reagent as it is. The
iron compound is preferably ferric sulfate in terms of a
good yield.
These iron compounds may be used in a solid state as
they are, but they may also be used in the form of a
solution. When they are used in the form of the solution,
a solvent to be used may be any one of the sulfoxides (1)

and the solvents as described above, and water is
preferable among them. On this occasion, the
concentration of the iron compound solution is preferably
from 0.1 to 10 mol/1, and more preferably from 0.5 to 5
mol/1.
The molar ratio of the cytosines (4) and the iron
compounds is preferably from 1:0.01 to 1:10, and more
preferably from 1:0.1 to 1:1 in terms of a good yield.
The reaction can be carried out at a temperature
optionally selected from the range of from 20 to 100°C.
The temperature is preferably from 20 to 70°C in terms of
a good yield.
In the case where the reaction is carried out in a
closed system, the reaction can be carried out under a
pressure optionally selected from the range of from the
atmospheric pressure (0.1 MPa) to 1.0 MPa, and the
reaction sufficiently proceeds even under the atmospheric
pressure. Furthermore, an atmosphere in the reaction may
be an inert gas such as argon or nitrogen, but the
reaction sufficiently proceeds even in the atmosphere of
air.
When the perfluoroalkyl halides of the general
formula (2) are gas at room temperature, they may be used
in a gaseous state as they are. On this occasion, they
may be used as a gas mixture after diluting them with a
gas such as argon, nitrogen, air, helium or oxygen,
wherein a molar fraction of the perfluoroalkyl halides

(2) is from 1 to 100%. In the case where the reaction is
carried out in a closed system, the perfluoroalkyl
halides (2) or the gas mixture thereof may be used as a
reaction atmosphere. On this occasion, the pressure can
be one optionally selected from the range of from the
atmospheric pressure (0.1 MPa) to 1.0 MPa, but the
reaction sufficiently proceeds even under the atmospheric
pressure. On the other hand, the perfluoroalkyl halides
(2) or the gas mixture thereof may be introduced by
bubbling into a reaction solution in an open system. On
this occasion, the introduction rate of the
perfluoroalkyl halides (2) or the gas mixture thereof may
be selected from the range of from 1 to 200 ml/min though
it depends on a scale of the reaction, an amount of the
catalyst, a temperature of the reaction, and a molar
fraction of the perfluoroalkyl halides (2) in the gas
mixture.
According to the process of the present invention, a
yield of the desired product can be improved by addition
of an acid. Examples of the acid include inorganic acids
such as sulfuric acid, hydrochloric acid, hydrogen
bromide, hydrogen iodide, nitric acid, phosphoric acid,
hexafluorophosphoric acid and tetrafluoroboric acid, and
organic acids such as formic acid, acetic acid, propionic
acid, oxalic acid, p-toluenesulfonic acid,
trifluoromethanesulfonic acid and trifluoroacetic acid.
These may be used in combination properly. It is

preferable to use sulfuric acid in terms of a good yield.
These acids may be used after diluting them. A
solvent in that case may be selected from the sulfoxides
(1) and the solvents as described above, and water, the
sulfoxides (1), or a solvent mixture of water and the
sulfoxides (1) is preferable among them.
The molar ratio of the cytosines (4) and the acids
is preferably from 1:0.001 to 1:5, and more preferably
from 1:0.01 to 1:2 in terms of a good yield.
There are no particular restrictions on a method for
isolating the desired product from the solution after the
reaction, and the desired product can be obtained by one
of the methods generally used such as solvent extraction,
column chromatography, preparative thin-layer
chromatography, preparative liquid chromatography,
recrystallization and sublimation.
In a case where the adenines of the general formula
(5) are used as a raw material, the production process is
shown in the following [Process-C], and an 8-
perfluoroalkyladenines represented by the general formula
(13) are obtained.

[Process-C]

wherein R9, R10, R11, R12, Rf and X are the same as those
described above.
In [Process-C], the sulfoxides (1) may be used as a
solvent as they are, but it is also possible to use a
solvent which does not adversely affect the reaction.
Specific examples of the solvent include water, N,N-
dimethylformamide, acetic acid, trifluoroacetic acid,
tetrahydrofuran, diethyl ether, ethyl acetate, acetone,
1,4-dioxane, tert-butyl alcohol, ethanol, methanol,
isopropyl alcohol, trifluoroethanol, hexamethylphosphoric
triamide, N-methyl-2-pyrrolidone, N,N,N',N'-
tetramethylurea, N,N'-dimethylpropyleneurea, and so on,
and these may be used in combination properly. The
solvent is preferably water, the sulfoxides (1) or a
solvent mixture of water and the sulfoxides (1) in terms
of a good yield.
The molar ratio of the adenines (5) and the
sulfoxides (1) is preferably from 1:1 to 1:200, and more

preferably from 1:10 to 1:100 in terms of a good yield.
The molar ratio of the adenines (5) and the
perfluoroalkyl halides (2) is preferably from 1:1 to
1:100, and more preferably from 1:1.5 to 1:10 in terms of
a good yield.
Examples of the peroxides include hydrogen peroxide,
a hydrogen peroxide-urea composite, tert-butyl peroxide,
peroxyacetic acid, and so on, and these may be used in
combination properly. The peroxide is preferably
hydrogen peroxide in terms of a good yield.
Hydrogen peroxide may be used after diluting it with
water. On this occasion, the concentration can be from 3
to 70% by weight, but commercially available 35% by
weight hydrogen peroxide may be used as it is. It is
more preferable to dilute hydrogen peroxide with water to
from 10 to 3 0% by weight in terms of a good yield and
safety.
The molar ratio of the adenines (5) and the
peroxides is preferably from 1:0.1 to 1:10, and more
preferably from 1:1.5 to 1:3 in terms of a good yield.
The iron compound is preferably an iron(II) salt in
terms of a good yield and examples thereof include
inorganic acid salts such as ferric sulfate, ammonium
ferric sulfate, ferric tetrafluoroborate, ferric chloride,
ferric bromide and ferric iodide, and organometallic
compounds such as ferric acetate, ferric oxalate,
bis(acetylacetonato)iron(II), ferrocene, and bis(η5-

pentamethylcyclopentadienyl)iron, and these may be used
in combination properly. In addition, an iron powder, an
iron(O) compound or an iron(I) salt may be used in
combination with an oxidizing reagent such as a peroxide,
so as to generate an iron(II) salt in the system. On
this occasion, hydrogen peroxide used for the reaction
may also be used as the oxidizing reagent as it is. The
iron compound is preferably ferric sulfate in terms of a
good yield.
These iron compounds may be used in a solid state as
they are, but they may also be used in the form of a
solution. When they are used in the form of the solution,
a solvent to be used may be any one of the sulfoxides (1)
and the solvents as described above, and water is
preferable among them. On this occasion, the
concentration of the iron compound solution is preferably
from 0.1 to 10 mol/1, and more preferably from 0.5 to 5
mol/1.
The molar ratio of the adenines (5) and the iron
compounds is preferably from 1:0.01 to 1:10, and more
preferably from 1:0.1 to 1:1 in terms of a good yield.
The reaction can be carried out at a temperature
optionally selected from the range of from 20 to 100°C.
The temperature is preferably from 20 to 70°C in terms of
a good yield.
In the case where the reaction is carried out in a
closed system, the reaction can be carried out under a

pressure optionally selected from the range of from the
atmospheric pressure (0.1 MPa) to 1.0 MPa, and the
reaction sufficiently proceeds even under the atmospheric
pressure. Furthermore, an atmosphere in the reaction may
be an inert gas such as argon or nitrogen, but the
reaction sufficiently proceeds even in the atmosphere of
air.
When the perfluoroalkyl halides of the general
formula (2) are gas at room temperature, they may be used
in a gaseous state as they are. On this occasion, it may
be used as a gas mixture after diluting them with a gas
such as argon, nitrogen, air, helium or oxygen, wherein a
molar fraction of the perfluoroalkyl halides (2) is from
1 to 100%. In the case where the reaction is carried out
in a closed system, the perfluoroalkyl halides (2) or the
gas mixture thereof may be used as a reaction atmosphere.
On this occasion, the pressure can be one optionally
selected from the range of from the atmospheric pressure
(0.1 MPa) to 1.0 MPa, but the reaction sufficiently
proceeds even under the atmospheric pressure. On the
other hand, the perfluoroalkyl halides (2) or the gas
mixture thereof may be introduced by bubbling into a
reaction solution in an open system. On this occasion,
the introduction rate of the perfluoroalkyl halides (2)
or the gas mixture thereof may be selected from the range
of from 1 to 200 ml/min though it depends on a scale of
the reaction, an amount of the catalyst, a temperature of

the reaction, and a molar fraction of the perfluoroalkyl
halides (2) in the gas mixture.
According to the process of the present invention, a
yield of the desired product can be improved by addition
of an acid. Examples of the acid include inorganic acids
such as sulfuric acid, hydrochloric acid, hydrogen
bromide, hydrogen iodide, nitric acid, phosphoric acid,
hexafluorophosphoric acid and tetrafluoroboric acid, and
organic acids such as formic acid, acetic acid, propionic
acid, oxalic acid, p-toluenesulfonic acid,
trifluoromethanesulfonic acid and trifluoroacetic acid.
These may be used in combination properly. It is.
preferable to use sulfuric acid in terms of a good yield.
These acids may be used after diluting them. A
solvent in that case may be selected from the sulfoxides
(1) and the solvents as described above, and water, the
sulfoxides (1), or a solvent mixture of water and the
sulfoxides (1) is preferable among them.
The molar ratio of the adenines (5) and the acids is
preferably from 1:0.001 to 1:5, and more preferably from
1:0.01 to 1:2 in terms of a good yield.
There are no particular restrictions on a method for
isolating the desired product from the solution after the
reaction, and the desired product can be obtained by one
of the methods generally used such as solvent extraction,
column chromatography, preparative thin-layer
chromatography, preparative liquid chromatography,

recrystallization and sublimation.
In a case where the guanines of the general formula
(6) are used as a raw material, the production process is
shown in the following [Process-D], and an 8-
perfluoroalkylguanines represented by the general formula
(14) are obtained.
[Process-D]

wherein R13, R14, R15, R16, Rf and X are the same as those
described above.
In [Process-D], the sulfoxides (1) may be used as a
solvent as they are, but it is also possible to use a
solvent which does not adversely affect the reaction.
Specific examples of the solvent include water, N,N-
dimethylformamide, acetic acid, trifluoroacetic acid,
tetrahydrofuran, diethyl ether, ethyl acetate, acetone,
1,4-dioxane, tert-butyl alcohol, ethanol, methanol,
isopropyl alcohol, trifluoroethanol, hexamethylphosphoric
triamide, N-methyl-2-pyrrolidone, N,N,N',N'-
tetramethylurea, N,N'-dimethylpropyleneurea, and so on,
and these may be used in combination properly. The

solvent is preferably water, the sulfoxides (1) or a
solvent mixture of water and the sulfoxides (1) in terms
of a good yield.
The molar ratio of the guanines (6) and the
sulfoxides (1) is preferably from 1:1 to 1:5000, and more
preferably from 1:10 to 1:3000 in terms of a good yield.
The molar ratio of the guanines (6) and the
perfluoroalkyl halides (2) is preferably from 1:1 to
1:100, and more preferably from 1:1.5 to 1:10 in terms of
a good yield.
Examples of the peroxides include hydrogen peroxide,
a hydrogen peroxide-urea composite, tert-butyl peroxide,
peroxyacetic acid, and so on, and these may be used in
combination properly. The peroxide is preferably
hydrogen peroxide in terms of a good yield.
Hydrogen peroxide may be used after diluting it with
water. On this occasion, the concentration can be from 3
to 70% by weight, but commercially available 35% by
weight hydrogen peroxide may be used as it is. It is
more preferable to dilute hydrogen peroxide with water to
from 10 to 30% by weight in terms of a good yield and
safety.
The molar ratio of the guanines (6) and the
peroxides is preferably from 1:0.1 to 1:10, and more
preferably from 1:1.5 to 1:3 in terms of a good yield.
The iron compound is preferably an iron(II) salt in
terms of a good yield and examples thereof include

inorganic acid salts such as ferric sulfate, ammonium
ferric sulfate, ferric tetrafluoroborate, ferric chloride,
ferric bromide and ferric iodide, and organometallic
compounds such as ferric acetate, ferric oxalate,
bis(acetylacetonato)iron(II), ferrocene, and bis(re-
pent amethylcyclopentadienyl) iron, and these may be used
in combination properly. In addition, an iron powder, an
iron(O) compound or an iron(I) salt may be used in
combination with an oxidizing reagent such as a peroxide,
so as to generate an iron(II) salt in the system. On
this occasion, hydrogen peroxide used for the reaction
may also be used as the oxidizing reagent as it is. The
iron compound is preferably ferric sulfate in terms of a
good yield.
These iron compounds may be used in a solid state as
they are, but they may also be used in the form of a
solution. When they are used in the form of the solution,
a solvent to be used may be any one of the sulfoxides (1)
and the solvents as described above, and water is
preferable among them. On this occasion, the
concentration of the iron compound solution is preferably
from 0.1 to 10 mol/1, and more preferably from 0.5 to 5
mol/1.
The molar ratio of the guanines (6) and the iron
compounds is preferably from 1:0.01 to 1:10, and more
preferably from 1:0.1 to 1:1 in terms of a good yield.
The reaction can be carried out at a temperature

optionally selected from the range of from 20 to 100°C.
The temperature is preferably from 20 to 70°C in terms of
a good yield.
In the case where the reaction is carried out in a
closed system, the reaction can be carried out under a
pressure optionally selected from the range of from the
atmospheric pressure (0.1 MPa) to 1.0 MPa, and the
reaction sufficiently proceeds even under the atmospheric
pressure. Furthermore, an atmosphere in the reaction may
be an inert gas such as argon or nitrogen, but the
reaction sufficiently proceeds even in the atmosphere of
air.
When the perfluoroalkyl halides of the general
formula (2) are gas at room temperature, they may be used
in a gaseous state as they are. On this occasion, it may
be used as a gas mixture as diluted with a gas such as
argon, nitrogen, air, helium or oxygen, wherein a molar
fraction of the perfluoroalkyl halides (2) is from 1 to
100%. In the case where the reaction is carried out in a
closed system, the perfluoroalkyl halides (2) or the gas
mixture thereof may be used as a reaction atmosphere. On
this occasion, the pressure can be one optionally
selected from the range of from the atmospheric pressure
(0.1 MPa) to 1.0 MPa, but the reaction sufficiently
proceeds even under the atmospheric pressure. On the
other hand, the perfluoroalkyl halides (2) or the gas
mixture thereof may be introduced by bubbling into a

reaction solution in an open system. On this occasion,
the introduction rate of the perfluoroalkyl halides (2)
or the gas mixture thereof may be selected from the range
of from 1 to 200 ml/min though it depends on a scale of
the reaction, an amount of the catalyst, a temperature of
the reaction, and a molar fraction of the perfluoroalkyl
halides (2) in the gas mixture.
According to the process of the present invention, a
yield of the desired product can be improved by addition
of an acid. Examples of the acid include inorganic acids
such as sulfuric acid, hydrochloric acid, hydrogen
bromide, hydrogen iodide, nitric acid, phosphoric acid,
hexafluorophosphoric acid and tetrafluoroboric acid, and
organic acids such as formic acid, acetic acid, propionic
acid, oxalic acid, p-toluenesulfonic acid,
trifluoromethanesulfonic acid and trifluoroacetic acid.
These may be used in combination properly. It is
preferable to use sulfuric acid in terms of a good yield.
These acids may be used after diluting them. A
solvent in that case may be selected from the sulfoxides
(1) and the solvents as described above, and water, the
sulfoxides (1) or a solvent mixture of water and the
sulfoxides (1) is preferable among them.
The molar ratio of the guanines (6) and the acids is
preferably from 1:0.001 to 1:5, and more preferably from
1:0.01 to 1:2 in terms of a good yield.
There are no particular restrictions on a method for

isolating the desired product from the solution after the
reaction, and the desired product can be obtained by one
of the methods generally used such as solvent extraction,
column chromatography, preparative thin-layer
chromatography, preparative liquid chromatography,
recrystallization and sublimation.
In a case where the hypoxanthines of the general
formula (7) are used as a raw material, the production
process is shown in the following [Process-E], and an 8-
perfluoroalkylhypoxanthines represented by the general
formula (15) are obtained.
[Process-E]

wherein R17, R18, Rf and X are the same as those described
above.
In [Process-E], the sulfoxides (1) may be used as a
solvent as they are, but it is also possible to use a
solvent which does not adversely affect the reaction.
Specific examples of the solvent include water, N,N-
dimethylformamide, acetic acid, trifluoroacetic acid,
tetrahydrofuran, diethyl ether, ethyl acetate, acetone,

1,4-dioxane, tert-butyl alcohol, ethanol, methanol,
isopropyl alcohol, trifluoroethanol, hexamethylphosphoric
triamide, N-methyl-2-pyrrolidone, N,N,N',N'-
tetramethylurea, N,N'-dimethylpropyleneurea, and so on,
and these may be used in combination properly. The
solvent is preferably water, the sulfoxides (1) or a
solvent mixture of water and the sulfoxides (1) in terms
of a good yield.
The molar ratio of the hypoxanthines (7) and the
sulfoxides (1) is preferably from 1:1 to 1:200, and more
preferably from 1:10 to 1:100 in terms of a good yield.
The molar ratio of the hypoxanthines (7) and the
perfluoroalkyl halides (2) is preferably from 1:1 to
1:100, and more preferably from 1:1.5 to 1:10 in terms of
a good yield.
Examples of the peroxides include hydrogen peroxide,
a hydrogen peroxide-urea composite, tert-butyl peroxide,
peroxyacetic acid, and so on, and these may be used in
combination properly. The peroxide is preferably
hydrogen peroxide in terms of a good yield.
Hydrogen peroxide may be used after diluting it with
water. On this occasion, the concentration may be from 3
to 70% by weight, but commercially available 35% by
weight hydrogen peroxide may be used as it is. It is
more preferable to dilute hydrogen peroxide with water to
from 10 to 30% by weight in terms of a good yield and
safety.

The molar ratio of the hypoxanthines (7) and the
peroxides is preferably from 1:0.1 to 1:10, and more
preferably from 1:1.5 to 1:3 in terms of a good yield.
The iron compound is preferably an iron(II) salt in
terms of a good yield and examples thereof include
inorganic acid salts such as ferric sulfate, ammonium
ferric sulfate, ferric tetrafluoroborate, ferric chloride,
ferric bromide and ferric iodide, and organometallic
compounds such as ferric acetate, ferric oxalate,
bis (acetylacetonato) iron (II) , ferrocene, and bis(η5-
pentamethylcyclopentadienyl)iron, and these may be used
in combination properly. In addition, an iron powder, an
iron(0) compound or an iron(I) salt may be used in
combination with an oxidizing reagent such as a peroxide,
so as to generate an iron(II) salt in the system. On
this occasion, hydrogen peroxide used for the reaction
may also be used as the oxidizing reagent as it is. The
iron compound is preferably ferric sulfate or ferrocene
in terms of a good yield.
These iron compounds may be used in a solid state as
they are, but they may also be used in the form of a
solution. When they are used in the form of the solution,
a solvent to be used may be any one of the sulfoxides (1)
and the solvents as described above, and water is
preferable among them. On this occasion, the
concentration of the iron compound solution is preferably
from 0.1 to 10 mol/1, and more preferably from 0.5 to 5

mol/1.
The molar ratio of the hypoxanthines (7) and the
iron compounds is preferably from 1:0.01 to 1:10, and
more preferably from 1:0.1 to 1:1 in terms of a good
yield.
The reaction can be carried out at a temperature
optionally selected from the range of from 20 to 100°C.
The temperature is preferably from 20 to 70°C in terms of
a good yield.
In the case where the reaction is carried out in a
closed system, the reaction can be carried out under a
pressure optionally selected from the range of from the
atmospheric pressure (0.1 MPa) to 1.0 MPa, and the
reaction sufficiently proceeds even under the atmospheric
pressure. Furthermore, an atmosphere in the reaction may
be an inert gas such as argon or nitrogen, but the
reaction sufficiently proceeds even in the atmosphere of
air.
When the perfluoroalkyl halides of the general
formula (2) are gas at room temperature, they may be used
in a gaseous state as they are. On this occasion, they
may be used as a gas mixture as diluted with a gas such
as argon, nitrogen, air, helium or oxygen, wherein a
molar fraction of the perfluoroalkyl halides (2) is from
1 to 100%. In the case where the reaction is carried out
in a closed system, the perfluoroalkyl halides (2) or the
gas mixture thereof may be used as a reaction atmosphere.

On this occasion, the pressure can be one optionally
selected from the range of from the atmospheric pressure
(0.1 MPa) to 1.0 MPa, but the reaction sufficiently
proceeds even under the atmospheric pressure. On the
other hand, the perfluoroalkyl halides (2) or the gas
mixture thereof may be introduced by bubbling into a
reaction solution in an open system. On this occasion,
the introduction rate of the perfluoroalkyl halides (2)
or the gas mixture thereof may be selected from the range
of from 1 to 200 ml/min though it depends on a scale of
the reaction, an amount of the catalyst, a temperature of
the reaction, and a molar fraction of the perfluoroalkyl
halides (2) in the gas mixture.
According to the process of the present invention, a
yield of the desired product can be improved by addition
of an acid. Examples of the acid include inorganic acids
such as sulfuric acid, hydrochloric acid, hydrogen
bromide, hydrogen iodide, nitric acid, phosphoric acid,
hexafluorophosphoric acid and tetrafluoroboric acid, and
organic acids such as formic acid, acetic acid, propionic
acid, oxalic acid, p-toluenesulfonic acid,
trifluoromethanesulfonic acid and trifluoroacetic acid.
These may be used in combination properly. It is
preferable to use sulfuric acid in terms of a good yield.
These acids may be used after diluting them. A
solvent in that case may be selected from the sulfoxides
(1) and the solvents as described above, and water, the

sulfoxides (1) or a solvent mixture of water and the
sulfoxides (1) is preferable among them.
The molar ratio of the hypoxanthines (7) and the
acids is preferably from 1:0.001 to 1:5, and more
preferably from 1:0.01 to 1:2 in terms of a good yield.
There are no particular restrictions on a method for
isolating the desired product from the solution after the
reaction, and the desired product can be obtained by one
of generally used methods such as solvent extraction,
column chromatography, preparative thin-layer
chromatography, preparative liquid chromatography,
recrystallization and sublimation.
In a case where the xanthines of the general formula
(8) are used as a raw material, the production process is
shown in the following [Process-F], and an 8-
perfluoroalkylxanthines represented by the general
formula (16) are obtained.
[Process-F]

wherein R19, R20, R21, Rf and X are the same as those
described above.

In [Process-F], the sulfoxides (1) may be used as a
solvent as they are, but it is also possible to use a
solvent which does not adversely affect the reaction.
Specific examples of the solvent include water, N,N-
dimethylformamide, acetic acid, trifluoroacetic acid,
tetrahydrofuran, diethyl ether, ethyl acetate, acetone,
1,4-dioxane, tert-butyl alcohol, ethanol, methanol,
isopropyl alcohol, trifluoroethanol, hexamethylphosphoric
triamide, N-methyl-2-pyrrolidone, N,N,N',N'-
tetramethylurea, N,N'-dimethylpropyleneurea, and so on,
and these may be used in combination properly. The
solvent is preferably water, the sulfoxides (1) or a
solvent mixture of water and the sulfoxides (1) in terms
of a good yield.
The molar ratio of the xanthines (8) and the
sulfoxides (1) is preferably from 1:1 to 1:5000, and more
preferably from 1:10 to 1:1000 in terms of a good yield.
The molar ratio of the xanthines (8) and the
perfluoroalkyl halides (2) is preferably from 1:1 to
1:100, and more preferably from 1:1.5 to 1:10 in terms of
a good yield.
Examples of the peroxides include hydrogen peroxide,
a hydrogen peroxide-urea composite, tert-butyl peroxide,
peroxyacetic acid, and so on, and these may be used in
combination properly. The peroxide is preferably
hydrogen peroxide in terms of a good yield.
Hydrogen peroxide may be used after diluting it with

water. On this occasion, the concentration can be from 3
to 70% by weight, but commercially available 35% by
weight hydrogen peroxide may be used as it is. It is
more preferable to dilute hydrogen peroxide with water to
from 10 to 30% by weight in terms of a good yield and
safety.
The molar ratio of the xanthines (8) and the
peroxides is preferably from 1:0.1 to 1:10, and more
preferably from 1:1.5 to 1:3 in terms of a good yield.
The iron compound is preferably an iron(II) salt in
terms of a good yield and examples thereof include
inorganic acid salts such as ferric sulfate, ammonium
ferric sulfate, ferric tetrafluoroborate, ferric chloride,
ferric bromide and ferric iodide, and organometallic
compounds such as ferric acetate, ferric oxalate,
bis(acetylacetonato)iron(II), ferrocene, and bis(η5-
pentamethylcyclopentadienyl)iron, and these may be used
in combination properly. In addition, an iron powder, an
iron(0) compound or an iron(I) salt may be used in
combination with an oxidizing reagent such as a peroxide,
so as to generate an iron(II) salt in the system. On
this occasion, hydrogen peroxide used for the reaction
may also be used as the oxidizing reagent as it is. The
iron compound is preferably ferric sulfate, ferric
tetrafluoroborate, ferrocene or an iron powder in terms
of a good yield.
These iron compounds may be used in a solid state as

they are, but they may also be used in the form of a
solution. When they are used in the form of the solution,
a solvent to be used may be any one of the sulfoxides (1)
and the solvents as described above, and water is
preferable among them. On this occasion, the
concentration of the iron compound solution is preferably
from 0.1 to 10 mol/1, and more preferably from 0.5 to 5
mol/1.
The molar ratio of the xanthines (8) and the iron
compounds is preferably from 1:0.01 to 1:10, and more
preferably from 1:0.1 to 1:1 in terms of a good yield.
The reaction can be carried out at a temperature
optionally selected from the range of from 20 to 100°C.
The temperature is preferably from 20 to 70°C in terms of
a good yield.
In the case where the reaction is carried out in a
closed system, the reaction can be carried out under a
pressure optionally selected from the range of from the
atmospheric pressure (0.1 MPa) to 1.0 MPa, and the
reaction sufficiently proceeds even under the atmospheric
pressure. Furthermore, an atmosphere in the reaction may
be an inert gas such as argon or nitrogen, but the
reaction sufficiently proceeds even in the atmosphere of
air.
When the perfluoroalkyl halides of the general
formula (2) are gas at room temperature, it may be used
in a gaseous state as they are. On this occasion, they

may be used as a gas mixture as diluted with a gas such
as argon, nitrogen, air, helium or oxygen, wherein a
molar fraction of the perfluoroalkyl halides (2) is from
1 to 100%. In the case where the reaction is carried out
in a closed system, the perfluoroalkyl halides (2) or the
gas mixture thereof may be used as a reaction atmosphere.
On this occasion, the pressure can be one optionally
selected from the range of from the atmospheric pressure
(0.1 MPa) to 1.0 MPa, but the reaction sufficiently
proceeds even under the atmospheric pressure. On the
other hand, the perfluoroalkyl halides (2) or the gas
mixture thereof may be introduced by bubbling into a
reaction solution in an open system. On this occasion,
the introduction rate of the perfluoroalkyl halides (2)
or the gas mixture thereof may be selected from the range
of from 1 to 200 ml/min though it depends on a scale of
the reaction, an amount of the catalyst, a temperature of
the reaction, and a molar fraction of the perfluoroalkyl
halides (2) in the gas mixture.
According to the process of the present invention, a
yield of the desired product can be improved by addition
of an acid. Examples of the acid include inorganic acids
such as sulfuric acid, hydrochloric acid, hydrogen
bromide, hydrogen iodide, nitric acid, phosphoric acid,
hexafluorophosphoric acid and tetrafluoroboric acid, and
organic acids such as formic acid, acetic acid, propionic
acid, oxalic acid, p-toluenesulfonic acid,

trifluoromethanesulfonic acid and trifluoroacetic acid.
These may be used in combination properly. It is
preferable to use sulfuric acid or tetrafluoroboric acid
in terms of a good yield.
These acids may be used after diluting them. A
solvent in that case may be selected from the sulfoxides
(1) and the solvents as described above, and water, the
sulfoxides (1) or a solvent mixture of water and the
sulfoxide compound (1) is preferable among them.
The molar ratio of the xanthines (8) and the acids
is preferably from 1:0.001 to 1:5, and more preferably
from 1:0.01 to 1:2 in terms of a good yield.
There are no particular restrictions on a method for
isolating the desired product from the solution after the
reaction, and the desired product can be obtained by one
of the methods generally used such as solvent extraction,
column chromatography, preparative thin-layer
chromatography, preparative liquid chromatography,
recrystallization and sublimation.
Of the compounds obtained by the production process
as described above, a 5-perfluoroalkyluracils represented
by the general formula (9) and an 8-
perfluoroalkylxanthines represented by the general
formula (10) are novel compounds and are expected to be
used as medical drugs or intermediates for medical and
agricultural chemicals.

EXAMPLES
Now, the present invention will be described in
detail with reference to examples, but it should be
understood that the present invention is by no means
restricted to these examples.
EXAMPLE 1

0.11 g (1.0 mmol) of uracil was weighed and placed
in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 2.0 ml of a
IN dimethyl sulfoxide solution, 1.0 ml of a 2.1 mol/1
dimethyl sulfoxide solution of trifluoromethyl iodide,
0.2 ml of a 3 0% hydrogen peroxide aqueous solution and
0.3 ml of a 1.0 mol/1 aqueous solution of ferric sulfate.
The mixture was stirred at 40 to 50°C for 20 minutes and
then the resulting solution was cooled to room
temperature. Formation of 5-trifluoromethyl uracil (19F-
NMR yield: 94%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 5-
Trifluoromethyluracil was obtained as a white solid (0.17
g, yield: 93%) by preparative thin-layer chromatography.
1H-NMR (deuterated acetone): δ8.09(s, 1H), 10.5(brs, 2H).
13C-NMR (deuterated acetone) : δ104.0 (q, JCF=32.4Hz),

123.6(q, JCF=268.2Hz) , 144.2 (q, JCF=5.9Hz), 150.9, 160.2.
19F-NMR (deuterated acetone): δ-64.1.
MS (m/z) : 180 [M]+.
EXAMPLE 2
Formation of 5-trifluoromethyluracil (19F-NMR yield:
80%) was confirmed in the same manner as in Example 1,
except that a 1.0 mol/1 of aqueous solution of ammonium
sulfate was used instead of the 1.0 mol/1 of aqueous
solution of ferric sulfate.
EXAMPLE 3
0.11 g (1.0 mmol) of uracil and 0.02 8 g (0.5 mmol)
of iron powder were weighed and placed in a 50 ml two-
neck flask equipped with a magnetic rotor and the
atmosphere in the flask was replaced with argon. The
following materials were added thereinto: 2.0 ml of
dimethyl sulfoxide, 2.0 ml of a IN dimethyl sulfoxide
solution of sulfuric acid, 1.0 ml of a 3.0 mol/1 dimethyl
sulfoxide solution of trifluoromethyl iodide and 0.2 ml
of a 30% hydrogen peroxide aqueous solution. The mixture
was stirred at 40 to 50°C for 20 minutes and then the
resulting solution was cooled to room temperature.
Formation of 5-trifluoromethyluracil (19F-NMR yield: 32%)
was confirmed in the same manner as in Example 1.
EXAMPLE 4
0.11 g (1.0 mmol) of uracil was weighed and placed
in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.

The following materials were added thereinto: 0.21 ml of
a 42% tetrafluoroboric acid aqueous solution, 2.0 ml of
dimethyl sulfoxide, 3.0 ml of a 2.0 mol/1 dimethyl
sulfoxide solution of trifluoromethyl iodide, 0.3 ml of a
1.0 mol/1 aqueous solution of ferric tetrafluoroborate
and 0.2 ml of a 30% hydrogen peroxide aqueous solution.
The mixture was stirred at 40 to 50°C for 20 minutes and
then the resulting solution was cooled to room
temperature. Formation of 5-trifluoromethyluracil (19F-
NMR yield: 94%) was confirmed in the same manner as in
Examp1e 1.
EXAMPLE 5
0.11 g (1.0 mmol) of uracil was weighed and placed
in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 2.0 ml of a
1N dimethyl sulfoxide solution of sulfuric acid, 3.0 ml
of a 2.0 mol/1 dimethyl sulfoxide solution of
trifluoromethyl iodide, 0.12 g of hydrogen peroxide-urea
composite and 0.3 ml of a 1 mol/1 aqueous solution of
ferric sulf ate. The mixture was stirred at 40 to 50°C
for 2 0 minutes and then the resulting solution was cooled
to room temperature. Formation of 5-trifluoromethyl
uracil (19F-NMR yield: 70%) was confirmed in the same
manner as in Example 1.
EXAMPLE 6
Formation of 5-trifluoromethyluracil (19F-NMR yield:

38%) was confirmed exactly in the same manner as in
Example 1, except that dimethyl sulfoxide was used
instead of the 1N dimethyl sulfoxide solution of sulfuric
acid.
EXAMPLE 7
0.11 g (1.0 mmol) of uracil was weighed and placed
in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with
trifluoromethyl iodide. The following materials were
added thereinto: 5.0 ml of dibutyl sulfoxide, 0.053 ml of
concentrated sulfuric acid, 0.2 ml of a 3 0% hydrogen
peroxide aqueous solution and 0.3 ml of a 1.0 mol/1
aqueous solution of ferric sulfate. The mixture was
stirred at 40 to 50°C for 20 minutes and then the
resulting solution was cooled to room temperature.
Formation of 5-trifluoromethyluracil (19F-NMR yield:
0.2%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard.
EXAMPLE 8
0.11 g (1.0 mmol) of uracil was weighed and placed
in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with
trifluoromethyl iodide. The following materials were
added thereinto: 5.0 g of diphenyl sulfoxide, 0.053 ml of
concentrated sulfuric acid, 0.2 ml of a 3 0% hydrogen
peroxide aqueous solution and 0.3 ml of a 1.0 mol/1
aqueous solution of ferric sulfate. The mixture was

stirred at 40 to 50°C for 20 minutes and then the
resulting solution was cooled to room temperature.
Formation of 5-trifluoromethyluracil (19F-NMR yield:
0.5%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard.
EXAMPLE 9
Formation of 5-trifluoromethyluracil (19F-NMR yield:
76%) was confirmed exactly in the same manner as in
Example 1, except that the reaction was carried out in
the atmosphere of air without the replacement with argon.
EXAMPLE 10
1.1 g (10 mmol) of uracil was weighed and placed in
a 100 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 2 0 ml of a
1N dimethyl sulfoxide solution of sulfuric acid, 22.5 ml
of dimethyl sulfoxide, 7.5 ml of a 2.0 mol/1 dimethyl
sulfoxide solution of trifluoromethyl iodide, 2.0 ml of a
30% hydrogen peroxide aqueous solution and 3.0 ml of a
1.0 mol/1 aqueous solution of ferric sulfate. The
mixture was stirred at 40 to 50°C for 30 minutes and then
the resulting solution was cooled to room temperature.
Formation of 5-trifluoromethyluracil (19F-NMR yield: 94%)
was confirmed in the same manner as in Example 1.
EXAMPLE 11
1.1 g (10 mmol) of uracil was weighed and placed in
a 100 ml two-neck flask equipped with a magnetic rotor

and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 0.055 ml of
concentrated sulfuric acid, 9 ml of dimethyl sulfoxide,
24.5 mmol of trifluoromethyl iodide, 2.0 ml of a 30%
hydrogen peroxide aqueous solution and 1.5 ml of a 1.0
mol/1 aqueous solution of ferric sulfate. The mixture
was stirred at 60 to 70°C for 10 minutes and then the
resulting solution was cooled to room temperature.
Formation of 5-trifluoromethyluracil (19F-NMR yield: 97%)
was confirmed in the same manner as in Example 1.
EXAMPLE 12
11.2 g (100 mmol) of uracil was weighed and placed
in a 300 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 80 ml of
dimethyl sulfoxide, 0.55 ml of concentrated sulfuric acid,
245 mmol of trifluoromethyl iodide, 20 ml of a 30%
hydrogen peroxide aqueous solution and 10 ml of a 1.5
mol/1 aqueous solution of ferric sulfate. The mixture
was stirred at 60 to 70°C for 100 minutes and then the
resulting solution was cooled to room temperature.
Formation of 5-trifluoromethyluracil (19F-NMR yield: 97%)
was confirmed in the same manner as in Example 1.

EXAMPLE 13

0.11 g (1.0 mmol) of uracil was weighed and placed
in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 2.0 ml of a
1N dimethyl sulfoxide solution of sulfuric acid, 1.3 ml
of tridecafluoro-1-iodohexane, 1.2 ml of dimethyl
sulfoxide, 0.3 ml of a 1.0 mol/l aqueous solution of
ferric sulfate and 0.2 ml of a 30% hydrogen peroxide
aqueous solution. The mixture was stirred at 40 to 50°C
for 2 0 minutes and then the resulting solution was cooled
to room temperature. Formation of 5-perfluorohexyluracil
(19F-NMR yield: 2 9%) was confirmed by 19F-NMR with
benzotrifluoride as an internal standard. 5-
Perfluorohexyluracil was obtained as a white solid (0.107
g, yield: 25%) by column chromatography.
1H-NMR (deuterated chloroform): δ8.01(d, JHF=5.7Hz, 1H),
11.59 (brs, 1H) , 11.80(d, JHF=4.8Hz, 1H) .
19F-NMR (deuterated chloroform) : 6-126.1 (q, JFF=7.0Hz, 2F) ,
-122.8(brs, 2F), -122.1(brs, 2F), -121.2(brs, 2F),
-108.5(m, 2F) , -80.5(t, JFF=9.5Hz, 3F)
MS (m/z) : 430[M]+.

EXAMPLE 14

0.18 g (1.0 mmol) of 6-trifluoromethyluracil and
0.058 g (0.3 mmol) of ferrocene were weighed and placed
in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 1.8 ml of
dimethyl sulfoxide, 2.0 ml of a 1N dimethyl sulfoxide
solution of sulfuric acid, 1.0 ml of a 2.1 mol/1 dimethyl
sulfoxide solution of trifluoromethyl iodide and 0.2 ml
of a 3 0% hydrogen peroxide aqueous solution. The mixture
was stirred at 60 to 70°C for 20 minutes and then the
resulting solution was cooled to room temperature.
Formation of 5,6-bis(trifluoromethyl)uracil (19F-NMR
yield: 63%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 5,6-
Bis(trifluoromethyl)uracil was obtained as a white solid
(0.12 g, yield: 48%) by preparative thin-layer
chromatography.
1H-NMR (deuterated acetone): 510.73(brs, 2H).
13C-NMR (deuterated acetone) : 5102.5 (q, JCF=32.7Hz),
120.6(q, JCF=277.3Hz) , 123. 2 (q, JCF=270 . 2Hz) , 147. 0 (q,
JCF=37.0Hz), 152.3, 161.2.
19F-NMR (deuterated acetone) : 5-64.8 (q, JFF=14.6Hz),

-58.4 (q, JFF=14.6Hz) .
MS (m/z) : 248[M]+.
EXAMPLE 15

0.17 g (1.0 mmol) of 6-methoxycarbonyluracil and
0.058 g (0.3 mmol) of ferrocene were weighed and placed
in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 1.8 ml of
dimethyl sulfoxide, 2.0 ml of a 1N dimethyl sulfoxide
solution of sulfuric acid, 1.0 ml of a 3.0 mol/1 dimethyl
sulfoxide solution of trifluoromethyl iodide and 0.2 ml
of a 30% hydrogen peroxide aqueous solution. The mixture
was stirred at 60 to 70°C for 20 minutes and then the
resulting solution was cooled to room temperature.
Formation of 6-methoxycarbonyl-5-trifluoromethyluracil
(19F-NMR yield: 84%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 6-
Methoxycarbonyl-5-trifluoromethyluracil was obtained as a
white solid (0.20 g, yield: 80%) by column chromatography.
1H-NMR (deuterated acetone): 53.94(s, 3H), 10.70(s, 1H),
11.10(brs, 1H).
13C-NMR (deuterated acetone) : 554.5, 100.8 (q, JCF=32.2Hz),
123.1(q, JCF=269.7Hz) , 147.4 (q, JCF=3.52Hz), 149.9, 160.1,

161.6.
19F-NMR (deuterated acetone): 5-60.6.
MS (m/z) : 238[M] + .
EXAMPLE 16

0.14 g (1.0 mmol) of 1,3-dimethyluracil was weighed
and placed in a 50 ml two-neck flask equipped with a
magnetic rotor and the atmosphere in the flask was
replaced with argon. The following materials were added
thereinto: 2.0 ml of a 1N dimethyl sulfoxide solution of
sulfuric acid, 1.0 ml of a 3.0 mol/l dimethyl sulfoxide
solution of trifluoromethyl iodide, 0.2 ml of a 30%
hydrogen peroxide aqueous solution and 0.3 ml of a 1.0
mol/1 aqueous solution of ferric sulfate. The mixture
was stirred at 40 to 50°C for 20 minutes and then the
resulting solution was cooled to room temperature.
Formation of 1,3-dimethyl-5-trifluoromethyluracil (19F-
NMR yield: 78%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 1,3-Dimethyl-
5-trifluoromethyluracil was obtained as a white solid
(0.12 g, yield: 44%) by preparative thin-layer
chromatography.
1H-NMR (deuterated acetone) : 53.25(s, 3H), 3.51(s, 3H) ,
8.23 (q, JHF=1.05Hz, 1H) .

13C-NMR (deuterated acetone): 527.8, 37.6, 102.9(q,
JCF=32.3Hz), 123. 8 (q, JCF=268 . 4Hz) , 146. 4 (q, JCF=5.91Hz),
151.9, 159.5.
19F-NMR (deuterated acetone): 6-60.6.
MS (m/z) : 208 [M]+.
EXAMPLE 17

0.16 g (1.0 mmol) of 6-amino-1,3-dimethyluracil was
weighed and placed in a 50 ml two-neck flask equipped
with a magnetic rotor and the atmosphere in the flask was
replaced with argon. The following materials were added
thereinto: 2.0 ml of a 1N dimethyl sulfoxide solution of
sulfuric acid, 1.0 ml of a 2.1 mol/l dimethyl sulfoxide
solution of trifluoromethyl iodide, 0.2 ml of a 30%
hydrogen peroxide aqueous solution and 0.3 ml of a 1.0
mol/l aqueous solution of ferric sulfate. The mixture
was stirred at 4 0 to 50°C for 2 0 minutes and then the
resulting solution was cooled to room temperature.
Formation of 6-amino-l,3-dimethyl-5-trifluoromethyluracil
(19F-NMR yield: 95%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 6-Amino-1,3-
dimethyl-5-trifluoromethyluracil was obtained as a white
solid (0.20 g, yield: 95%) by column chromatography.
1H-NMR (deuterated chloroform): 53.29(s, 3H), 3.53(s, 3H),

6.20(s, 2H).
13C-NMR (deuterated chloroform): 528.0, 29.7, 80.5(q,
JCF=30.2Hz) , 125.5(q, JCF=269. lHz) , 150.4, 153.2, 159.8.
19F-NMR (deuterated chloroform): 5-54.9.
MS (m/z) : 223 [M]+.
EXAMPLE 18

0.26 g (1.0 mmol) of 6-tert-butoxycarbonylamino-1,3-
dimethyluracil was weighed and placed in a 50 ml two-neck
flask equipped with a magnetic rotor and the atmosphere
in the flask was replaced with argon. The following
materials were added thereinto: 2.0 ml of a 1N dimethyl
sulfoxide solution of sulfuric acid, 1.0 ml of a 2.1
mol/l dimethyl sulfoxide solution of trifluoromethyl
iodide, 0.2 ml of a 30% hydrogen peroxide aqueous
solution and 0.3 ml of a 1.0 mol/l aqueous solution of
ferric sulfate. The mixture was stirred at 40 to 50°C
for 20 minutes and then the resulting solution was cooled
to room temperature. Formation of 6-tert-
butoxycarbonylamino-1,3-dimethyl-5-trifluoromethyluracil
(19F-NMR yield: 95%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 6-tert-
Butoxycarbonylamino-1,3-dimethyl-5-trifluoromethyluracil
was obtained as a white solid (0.30 g, yield: 93%) by

column chromatography.
1H-NMR (deuterated chloroform): 5l.51(s, 9H) , 3.32 (s, 3H) ,
3.46(s, 3H), 6.89(brs, 1H).
13C-NMR (deuterated chloroform): 527.9, 28.5, 32.2, 84.2,
98.4(q, JCF=22.8Hz), 122. 8 (q, JCF=271. 5Hz) , 147.5, 150.6,
151.3, 158.6.
19F-NMR (deuterated chloroform): δ-54.8.
MS (m/z) : 250 [M-OC4H9]+.
EXAMPLE 19

0.16 g (1.0 mmol) of 6-(2-chloromethyl)uracil and
0.058 g (0.3 mmol) of ferrocene were weighed and placed
in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 1.8 ml of
dimethyl sulfoxide, 2.0 ml of a in dimethyl sulfoxide
solution of sulfuric acid, 1.0 ml of a 2.1 mol/l dimethyl
sulfoxide solution of trifluoromethyl iodide and 0.2 ml
of a 3 0% hydrogen peroxide aqueous solution. The mixture
was stirred at 60 to 70°C for 20 minutes and then the
resulting solution was cooled to room temperature.
Formation of 6-(2-chloromethyl)-5-trifluoromethyluracil
(19F-NMR yield: 55%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 6-(2-

Chloromethyl)-5-trifluoromethyluracil was obtained as a
white solid (0.10 g, yield: 45%) by preparative thin-
layer chromatography.
1H-NMR (deuterated dimethyl sulfoxide): 54.47(s, 2H) ,
11.78(brs, 1H), 11.82(brs, 1H).
13C-NMR (deuterated dimethyl sulfoxide): 538.8, 100.9(q,
JCF=30.7Hz), 123.6 (q, JCF=270 . 9Hz) , 150.3, 153.9, 160.9.
19F-NMR (deuterated dimethyl sulfoxide): δ-56.5.
MS (m/z) : 228[M]+.
EXAMPLE 20

0.17 g (1.0 mmol) of 6-carboxyuracil and 0.058 g
(0.3 mmol) of ferrocene were weighed and placed in a 50
ml two-neck flask equipped with a magnetic rotor and the
atmosphere in the flask was replaced with argon. The
following materials were added thereinto: 1.8 ml of
dimethyl sulfoxide, 2.0 ml of a in dimethyl sulfoxide
solution of sulfuric acid, 1.0 ml of a 3.0 mol/l dimethyl
sulfoxide solution of trifluoromethyl iodide and 0.2 ml
of a 3 0% hydrogen peroxide aqueous solution. The mixture
was stirred at 60 to 70°C for 20 minutes and then the
resulting solution was cooled to room temperature.
Formation of 6-carboxy-5-trifluoromethyluracil (19F-NMR
yield: 95%) was confirmed by 19F-NMR with 2,2,2-

trifluoroethanol as an internal standard. 6-Carboxy-5-
trifluoromethyluracil was obtained (0.076 g, yield: 34%)
by column chromatography.
1H-NMR (deuterated dimethyl sulfoxide) : 5ll.71(brs, 1H) ,
12.13(brs, 1H).
13C-NMR (deuterated dimethyl sulfoxide): 597.2(q,
JCF=31.5HZ), 122.9(q, JCF=269. 9Hz) , 149.8, 150.3, 160.6,
162.3.
19F-NMR (deuterated dimethyl sulfoxide): 5-58.6.
MS (m/z): 223[M-H]+.
EXAMPLE 21

0.24 g (1.0 mmol) of uridine was weighed and placed
in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 1.5 ml of
dimethyl sulfoxide, 2 ml of a in dimethyl sulfoxide
solution of sulfuric acid, 1 ml of a 3.0 mol/l dimethyl
sulfoxide solution of trifluoromethyl iodide, 0.3 ml of a
1 mol/l aqueous solution of ferric sulfate and 0.2 ml of
a 3 0% hydrogen peroxide aqueous solution. The mixture
was stirred at 40 to 50°C for 20 minutes and then the

resulting solution was cooled to room temperature.
Formation of 5-trifluoromethyluridine (19F-NMR yield:
51%) was confirmed by 19F-NMR with 2,2,2-trifluoroethanol
as an internal standard. 5-Trifluoromethyluridine was
obtained (0.071 g, yield: 23%) by column chromatography.
1H-NMR (deuterated dimethyl sulfoxide): 52.84(brs, 3H),
3.88(m, 3H), 4.60(m, 1H), 4.32(d, J=13.6Hz, 2H), 4.60(brs,
1H) , 5.88(d, J=13.6Hz, 1H) , 8.88(s, 1H) .
19F-NMR (deuterated dimethyl sulfoxide): δ-61.8.
EXAMPLE 22

0.37 g (1.0 mmol) of 2',3',5'-tri-O-acetyluridine
and 0.058 g (0.3 mmol) of ferrocene were weighed and
placed in a 50 ml two-neck flask equipped with a magnetic
rotor and the atmosphere in the flask was replaced with
argon. The following materials were added thereinto: 1.8
ml of dimethyl sulfoxide, 2.0 ml of a in dimethyl
sulfoxide solution of sulfuric acid, 1.0 ml of a 2.1
mol/l dimethyl sulfoxide solution of trifluoromethyl
iodide and 0.2 ml of a 30% hydrogen peroxide aqueous
solution. The mixture was stirred at 60 to 70°C for 20

minutes and then the resulting solution was cooled to
room temperature. Formation of 5-trifluoromethyl-
2',3',5'-tri-O-acetyluridine (19F-NMR yield: 45%) was
confirmed by 19F-NMR with 2,2,2-trifluoroethanol as an
internal standard. 5-Trifluoromethyl-2',3',5'-tri-O-
acetyluridine was obtained as a white solid (0.17 g,
yield: 40%) by column chromatography.
1H-NMR (deuterated chloroform) : 52.11(s, 3H), 2.13(s, 3H) ,
2.14(s, 3H), 4.34(d, J=13.6Hz, 1H), 4.43(m, 1H), 4.43(dd,
J=3.2Hz, 13.6Hz, 1H), 5.34(t, J=5.4Hz, 1H), 5.37(t,
J=5.4Hz, 1H) , 6.07(d, J=5.4Hz, 1H) , 8.01(s, 1H) , 9.48(s,
1H) .
13C-NMR (deuterated chloroform): δ20.3, 20.4, 62.7, 69.9,
73.2, 80.5, 87.7, 106.2(q, JCF=33.3Hz), 121.6(q,
JCF=270.3Hz) , 140.2 (q, JCF=6.0Hz), 149.3, 158.0, 169.6,
169.7, 170.2.
19F-NMR (deuterated chloroform): δ-64.0.
EXAMPLE 23

0.23 g (1.0 mmol) of 2'-deoxyuridine was weighed and
placed in a 50 ml two-neck flask equipped with a magnetic
rotor and the atmosphere in the flask was replaced with

argon. The following materials were added thereinto: 2.0
ml of a in dimethyl sulfoxide solution of sulfuric acid,
1.0 ml of a 2.1 mol/l dimethyl sulfoxide solution of
trifluoromethyl iodide, 0.2 ml of a 3 0% hydrogen peroxide
aqueous solution and 0.3 ml of a 1.0 mol/l aqueous
solution of ferric sulfate. The mixture was stirred at
40 to 50°C for 20 minutes and then the resulting solution
was cooled to room temperature. Formation of 5-
trifluoromethyl-2'-deoxyuridine (19F-NMR yield: 85%) was
confirmed by 19F-NMR with 2,2,2-trifluoroethanol as an
internal standard. 5-Trifluoromethyl-2'-deoxyuridine was
obtained as a white solid (0.17 g, yield: 58%) by column
chromatography.
1H-NMR (deuterated chloroform): 52.35(ddd, J=6.10Hz,
6.25HZ, 13.53HZ, 1H), 2.39(ddd, J=3.61Hz, 6.25Hz, 13.53HZ,
1H), 3.86(dd, J=11.7Hz, 15.3Hz, 2H), 4.02(dd, J=3.61Hz,
6.10HZ, 1H), 4.46(brs, 2H), 4.53(brs, 1H), 6.27(t,
J=6.25Hz, 1H) , 8.84(s, 1H) , 10.45(s, 1H) .
13C-NMR (deuterated chloroform): δ42.0, 62.0, 71.4, 86.9,
89.0, 104. 5(q, JCF=32.4Hz), 123. 7 (q, JCF=268 . 6Hz) , 143.1 (q,
JCF=5.66Hz), 150.5, 159.4.
19F-NMR (deuterated chloroform): 5-63.7.

EXAMPLE 24

0.32 g (1.0 mmol) of 3',5'-di-O-acetyl-2'-
deoxyuridine and 0.058 g (0.3 mmol) of ferrocene were
weighed and placed in a 50 ml two-neck flask equipped
with a magnetic rotor and the atmosphere in the flask was
replaced with argon. The following materials were added
thereinto: 1.8 ml of dimethyl sulfoxide, 2.0 ml of a 1N
dimethyl sulfoxide solution of sulfuric acid, 1.0 ml of a
2.1 mol/l dimethyl sulfoxide solution of trifluoromethyl
iodide and 0.2 ml of a 30% hydrogen peroxide aqueous
solution. The mixture was stirred at 60 to 70°C for 20
minutes and then the resulting solution was cooled to
room temperature. Formation of 5-trifluoromethyl-3',5'-
di-O-acetyl-2'-deoxyuridine (19F-NMR yield: 75%) was
confirmed by 19F-NMR with trifluoroethanol as an internal
standard. 5-Trifluoromethyl-3',5'-di-O-acetyl-2'-
deoxyuridine was obtained as a white solid (0.19 g,
yield: 5 0%) by column chromatography.
1H-NMR (deuterated chloroform): δ2.10(s, 3H), 2.13(s, 3H),
2.19(ddd, J=6.63Hz, 8.00HZ, 14.34Hz, 1H), 2.63(ddd,

J=1.96Hz, 5.72HZ, 14.34Hz, 1H), 4.28-4.37(m, 2H), 4.44(dd,
J=2.66Hz, 11.77HZ, 1H), 5.23(td, J=1.96Hz, 6.63Hz, 1H),
6.28(dd, J=5.72Hz, 8.00Hz, 1H) , 8.09(s, 1H) , 9.27(s, 1H) .
13C-NMR (deuterated chloroform): δ20.5, 20.9, 38.7, 63.7,
74.0, 83.1, 86.1, 105.7(q, JCF=33.3Hz), 121.7(q,
JCF=270.2Hz) , 140.0 (q, JCF=5.91Hz), 149.2, 158.1, 170.2,
170.4.
19F-NMR (deuterated chloroform): δ-63.7.
EXAMPLE 25

0.11 g (1.0 mmol) of cytosine was weighed and placed in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 2.0 ml of
dimethyl sulfoxide, 2.0 ml of a 1N dimethyl sulfoxide
solution of sulfuric acid, 1.0 ml of a 3.0 mol/l dimethyl
sulfoxide solution of trifluoromethyl iodide, 0.2 ml of a
3 0% hydrogen peroxide aqueous solution and 0.3 ml of a
1.0 mol/l aqueous solution of ferric sulfate. The
mixture was stirred at 40 to 50°C for 20 minutes and then
the resulting solution was cooled to room temperature.
Formation of 5-trifluoromethylcytosine (19F-NMR yield:
27%) was confirmed by 19F-NMR with 2,2,2-trifluoroethanol
as an internal standard. 5-Trifluoromethylcytosine was

obtained as a white solid (0.010 g, yield: 5.6%) by
column chromatography.
1H-NMR (deuterated dimethyl sulfoxide): 56.95(brs, 2H),
7.72(brs, 2H), 7.95(s, 1H).
13C-NMR (deuterated dimethyl sulfoxide): δ94.3(q,
JCF=33.5Hz), 124.2 (q, JCF=268 . 7Hz) , 145.8, 156.0, 161.5.
19F-NMR (deuterated dimethyl sulfoxide): 5-60.8.
MS (m/z) : 181 [M]+.
EXAMPLE 26

0.15 g (1.0 mmol) of N4-acetylcytosine was weighed
and placed in a 50 ml two-neck flask equipped with a
magnetic rotor and the atmosphere in the flask was
replaced with argon. The following materials were added
thereinto: 17 ml of dimethyl sulfoxide, 2.0 ml of a 1N
dimethyl sulfoxide solution of sulfuric acid, 1.0 ml of a
3.0 mol/l dimethyl sulfoxide solution of trifluoromethyl
iodide, 0.2 ml of a 30% hydrogen peroxide aqueous
solution and 0.3 ml of a 1.0 mol/l aqueous solution of
ferric sulfate. The mixture was stirred at 40 to 50°C
for 20 minutes and then the resulting solution was cooled
to room temperature. Formation of N4-acetyl-5-
trifluoromethylcytosine (19F-NMR yield: 35%) was

confirmed by 19F-NMR with 2,2,2-trifluoroethanol as an
internal standard. N4-acetyl-5-trifluoromethylcytosine
was obtained as a white solid (0.067 g, yield: 30%) by
column chromatography.
1H-NMR (deuterated dimethyl sulfoxide): δ2.56(s, 3H),
8.04(s, 1H), 11.58(brs, 2H).
13C-NMR (deuterated dimethyl sulfoxide): δ23.0, 102.3(q,
JCF=31.9Hz), 123.4 (q, JCF=268 . 8Hz) , 144.7 (q, JCF=5.6Hz),
151.2, 160.5, 172.1.
19F-NMR (deuterated dimethyl sulfoxide): 5-61.8.
MS (m/z) : 224 [M+H] + .
EXAMPLE 2 7

0.24 g (1.0 mmol) of cytidine was weighed and placed in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 4.0 ml of
dimethyl sulfoxide, 1.0 ml of a 3.0 mol/l dimethyl
sulfoxide solution of trifluoromethyl iodide, 0.3 ml of a
1.0 mol/l aqueous solution of ferric sulfate and 0.2 ml
of a 30% hydrogen peroxide aqueous solution. The mixture
was stirred at 40 to 50°C for 20 minutes and then the

resulting solution was cooled to room temperature.
Formation of 5-trifluoromethylcytidine (19F-NMR yield:
24%) was confirmed by 19F-NMR with 2,2,2-trifluoroethanol
as an internal standard. 5-Trifluoromethylcytidine was
obtained (0.034 g, yield: 11%) by column chromatography.
1H-NMR (deuterated dimethyl sulfoxide) : 53.52 (m, 1H) ,
3.70(m, 1H), 3.96(m, 3H), 5.00(d, J=13.6Hz, 1H), 5.28(t,
J=5.4Hz, 1H), 5.48(d, J=13.6Hz, 1H), 5.76(m, 1H),
7.16(brs, 1H), 7.72(brs, 2H), 8.84(s, 1H).
19F-NMR (deuterated dimethyl sulfoxide): δ-60.9.
EXAMPLE 28

0.15 g (1.0 mmol) of 2'-deoxycytidine was weighed
and placed in a 50 ml two-neck flask equipped with a
magnetic rotor and the atmosphere in the flask was
replaced with argon. The following materials were added
thereinto: 2.0 ml of dimethyl sulfoxide, 2.0 ml of a 1N
dimethyl sulfoxide solution of sulfuric acid, 1.0 ml of a
3.0 mol/l dimethyl sulfoxide solution of trifluoromethyl
iodide, 0.2 ml of a 30% hydrogen peroxide aqueous
solution and 0.3 ml of a 1.0 mol/l aqueous solution of
ferric sulfate. The mixture was stirred at 40 to 50°C

for 20 minutes and then the resulting solution was cooled
to room temperature. Formation of 5-trifluoromethyl-2'-
deoxycytidine (19F-NMR yield: 11%) was confirmed by 19F-
NMR with 2,2,2-trifluoroethanol as an internal standard.
5-Trifluoromethyl-2'-deoxycytidine was obtained as a
white solid (0.01 g, yield: 3.3%) by column
chromatography.
1H-NMR (deuterated dimethyl sulfoxide): 52.16(m, 2H),
3.62(m, 2H), 3.82(m, 1H), 4.20(m, 1H), 5.06(d, J=12.5Hz,
1H), 5.19(d, J=12.5Hz, 1H), 6.04(t, J=5.6Hz, 1H),
7.04(brs, 1H), 7.64(brs; 2H), 8.60(s, 1H).
19F-NMR (deuterated dimethyl sulfoxide): δ-60.8.
EXAMPLE 29

0.13 g (1.0 mmol) of adenine was weighed and placed in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 2.0 ml of
dimethyl sulfoxide, 2.0 ml of a in dimethyl sulfoxide
solution of sulfuric acid, 1.0 ml of a 3.0 mol/l dimethyl
sulfoxide solution of trifluoromethyl iodide, 0.2 ml of a
3 0% hydrogen peroxide aqueous solution and 0.3 ml of a
1.0 mol/l aqueous solution of ferric sulfate. The
mixture was stirred at 40 to 50°C for 20 minutes and then

the resulting solution was cooled to room temperature.
Formation of 8-trifluoromethyladenine (19F-NMR yield:
26%) was confirmed by 19F-NMR with 2,2,2-trifluoroethanol
as an internal standard. 8-Trifluoromethyladenine was
obtained as a white solid (0.02 g, yield: 10%) by
preparative thin-layer chromatography.
1H-NMR (deuterated dimethyl sulfoxide): δ8.31(s, 1H),
14.08(brs, 2H).
13C-NMR (deuterated dimethyl sulfoxide): 5119.9, 121.0(q,
JCF=270.2Hz), 147.1, 147.1, 150.9, 156.8.
19F-NMR (deuterated dimethyl sulfoxide): 5-62.9.
MS (m/z): 203[M]+
EXAMPLE 30

0.27 g (1.0 mmol) of adenosine was weighed and
placed in a 50 ml two-neck flask equipped with a magnetic
rotor and the atmosphere in the flask was replaced with
argon. The following materials were added thereinto: 4.0
ml of dimethyl sulfoxide, 1.0 ml of a 3.0 mol/l dimethyl
sulfoxide solution of trifluoromethyl iodide, 0.3 ml of a
1.0 mol/l aqueous solution of ferric sulfate and 0.2 ml
of a 30% hydrogen peroxide aqueous solution. The mixture
was stirred at 40 to 50°C for 20 minutes and then the

resulting solution was cooled to room temperature.
Formation of 8-trifluoromethyladenosine (19F-NMR yield:
6.7%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 8-
Trifluoromethyladenosine was obtained as a white solid
(0.01 g, yield: 3.1%) by column chromatography.
1H-NMR (deuterated dimethyl sulfoxide): δ3.62(m, 2H),
4.04(m, 1H), 4.23(m, 1H), 5.05(dd, 1H), 5.24(m, 1H),
5.52(m, 2H), 5.81(d, 1H) , 7.92(brs, 2H) , 8.24(s, 1H) .
19F-NMR (deuterated dimethyl sulfoxide): δ-60.2.
EXAMPLE 31

0.15 g (1.0 mmol) of 2,6-diaminopurine was weighed
and placed in a 50 ml two-neck flask equipped with a
magnetic rotor and the atmosphere in the flask was
replaced with argon. The following materials were added
thereinto: 4.0 ml of dimethyl sulfoxide, 1.0 ml of a 3.0
mol/l dimethyl sulfoxide solution of trifluoromethyl
iodide, 0.3 ml of a 1.0 mol/l aqueous solution of ferric
sulfate and 0.2 ml of a 30% hydrogen peroxide aqueous
solution. The mixture was stirred at 40 to 50°C for 20
minutes and then the resulting solution was cooled to
room temperature. Formation of 2,6-diamino-8-
trifluoromethylpurine (19F-NMR yield: 45%) was confirmed

by 19F-NMR with 2,2,2-trifluoroethanol as an internal
standard. 2,6-Diamino-8-trifluoromethylpurine was
obtained as a white solid (0.050 g, yield: 23%) by column
chromatography.
Hl-NMR (deuterated dimethyl sulfoxide): S6.17(s, 2H) ,
7.26 (s, 2H) , 12.2(brs, 1H) .
13C-NMR (deuterated dimethyl sulfoxide): 5114.8, 116.0(q,
JCF=269.1Hz), 144.3, 152.7, 157.0, 161.7.
19F-NMR (deuterated dimethyl sulfoxide): δ-62.6.
MS (m/z): 218[M]+.
EXAMPLE 32

0.15 g (1.0 mmol) of 2,6-diaminopurine was weighed
and placed in a 50 ml two-neck flask equipped with a
magnetic rotor and the atmosphere in the flask was
replaced with argon. The following materials were added
thereinto: 3.0 ml of dimethyl sulfoxide, 2.0 ml of a 1N dimethyl sulfoxide solution of sulfuric acid, 1.3 ml of
tridecafluoro-1-iodohexane, 0.3 ml of a 1.0 mol/l aqueous
solution of ferric sulfate and 0.2 ml of a 30% hydrogen
peroxide aqueous solution. The mixture was stirred at 40
to 50°C for 20 minutes and then the resulting solution
was cooled to room temperature. Formation of 2,6-
diamino-8-perfluorohexylpurine (19F-NMR yield: 10%) was

confirmed by 19F-NMR with 2,2,2-trifluoroethanol as an
internal standard. 2,6-Diamino-8-perfluorohexylpurine
was obtained as a white solid (0.018 g, yield: 4.0%) by
column chromatography.
1H-NMR (deuterated dimethyl sulfoxide): δ6.20(s, 2H) ,
7.31(s, 2H), 12.2(brs, 1H).
19F-NMR (deuterated dimethyl sulfoxide): δ-126.2(q,
JFF=4.7Hz, 2F) , -122.9(brs, 2F) , -121.9 (m, 4F) , -108.9 (m,
2F) , -80.7(t, JFF=9.5Hz, 3F)
MS (m/z) : 469[M+H]+.
EXAMPLE 33

0.15 g (1.0 mmol) of guanine was weighed and placed in a 500 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 197 ml of
dimethyl sulfoxide, 2.0 ml of a in dimethyl sulfoxide
solution of sulfuric acid, 1.0 ml of a 3.0 mol/l dimethyl
sulfoxide solution of trifluoromethyl iodide, 0.2 ml of a
30% hydrogen peroxide aqueous solution and 0.3 ml of a
1.0 mol/l aqueous solution of ferric sulfate. The
mixture was stirred at 40 to 50°C for 20 minutes and then
the resulting solution was cooled to room temperature.
Formation of 8-trifluoromethylguanine (19F-NMR yield:

46%) was confirmed by 19F-NMR with 2,2,2-trifluoroethanol
as an internal standard. 8-Trifluoromethylguanine was
obtained as a white solid (0.019 g, yield: 9%) by column
chromatography.
1H-NMR (deuterated dimethyl sulfoxide): 56.60(brs, 2H),
10.81(brs, 1H), 13.73(brs, 1H).
13C-NMR (deuterated dimethyl sulfoxide): δ116.3, 119.2(q,
JCF=269.3Hz) , 134.9 (q, JCF=40.7Hz), 152.8, 154.7, 156.6.
19F-NMR (deuterated dimethyl sulfoxide): δ-63.0.
MS (m/z) : 218 [M-H]-.
EXAMPLE 34

0.41 g (1.0 mmol) of 2',3',5'-tri-O-acetylguanosine
was weighed and placed in a 50 ml two-neck flask equipped
with a magnetic rotor and the atmosphere in the flask was
replaced with argon. The following materials were added
thereinto: 2.0 ml of dimethyl sulfoxide, 2.0 ml of a 1N dimethyl sulfoxide solution of sulfuric acid, 1.0 ml of a
3.0 mol/l of dimethyl sulfoxide solution of
trifluoromethyl iodide, 0.3 ml of a 1.0 mol/l aqueous
solution of ferric sulfate and 0.2 ml of a 30% hydrogen
peroxide aqueous solution. The mixture was stirred at 40

to 50°C for 20 minutes and then the resulting solution
was cooled to room temperature. Formation of 8-
trifluoromethyl-2',3',5'-tri-O-acetylguanosine (19F-NMR
yield: 51%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 8-
Trifluoromethyl-2',3',5'-tri-O-acetylguanosine was
obtained as a yellow solid (0.22 g, yield: 47%) by silica
gel column chromatography.
1H-NMR (deuterated chloroform): 52.03(s, 3H), 2.13(s, 3H),
2.16(s, 3H), 4.30(m, 1H), 4.44(m, 2H), 5.87(t, J=5.0Hz,
1H), 5.94(d, J=5.0Hz, 1H), 6.47(brs, 2H), 12.1(s, 1H).
13C-NMR (deuterated chloroform): δ20.3, 20.5, 20.6, 62.9,
70.6, 71.6, 77.2, 80.6, 87.6, 116.4, 118.3(q,
JCF=270.5Hz), 152.6, 154.6, 158.9, 169.5, 169.5, 170.8.
19F-NMR (deuterated chloroform): δ-61.5.
EXAMPLE 35

0.39 g (1.0 mmol) of 2',3',5'-tri-O-acetylinosine
was weighed and placed in a 50 ml two-neck flask equipped
with a magnetic rotor and the atmosphere in the flask was
replaced with argon. The following materials were added
thereinto: 5.0 ml of dimethyl sulfoxide, 2.0 ml of a 1N

dimethyl sulfoxide solution of sulfuric acid, 1.0 ml of a
3.0 mol/l of dimethyl sulfoxide solution of
trifluoromethyl iodide, 0.3 ml of a 1.0 mol/l aqueous
solution of ferric sulfate and 0.2 ml of a 30% hydrogen
peroxide aqueous solution. The mixture was stirred at 4 0
to 50°C for 20 minutes and then the resulting solution
was cooled to room temperature. Formation of 8-
trifluoromethyl-2',3',5'-tri-O-acetylinosine (19F-NMR
yield: 7.0%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 8-
Trifluoromethyl-2',3',5'-tri-O-acetylinosine was obtained
(0.018 g, yield: 4.0%) by column chromatography.
1H-NMR (deuterated dimethyl sulfoxide): 52.08(s, 6H),
2.16(s, 3H), 4.35-4.45(m, 2H), 4.51(dd, J=3.6, 11.3Hz,
lH)5.73(dd, J=5.5, 5.6Hz, 1H), 6.08(d, J=5.5Hz, 1H),
6.27(dd, J=5.6Hz, 1H), 8.26(s, 1H) , 12.49(brs, 1H) .
13C-NMR (deuterated dimethyl sulfoxide): 520.2, 20.5,
20.7, 62.8, 70.3, 72.0, 80.7, 88.0, 118.1(q, JCF=271.7Hz),
124.2, 138.2(q, JCF=40.7Hz), 147.2, 150.1, 158.6, 169.2,
169.5, 170.5.
19F-NMR (deuterated dimethyl sulfoxide): δ-61.5.
EXAMPLE 36

0.14 g (1.0 mmol) of hypoxanthine and 0.058 g (0.3

mmol) of ferrocene were weighed and placed in a 50 ml
two-neck flask equipped with a magnetic rotor and the
atmosphere in the flask was replaced with argon. The
following materials were added thereinto: 2.0 ml of
dimethyl sulfoxide, 2.0 ml of a in dimethyl sulfoxide
solution of sulfuric acid, 1.0 ml of a 3.0 mol/l of
dimethyl sulfoxide solution of trifluoromethyl iodide and
0.2 ml of a 30% hydrogen peroxide aqueous solution. The
mixture was stirred at 60 to 70°C for 20 minutes and then
the resulting solution was cooled to room temperature.
Formation of 8-trifluoromethylhypoxanthine (19F-NMR
yield: 24%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 8-
Trifluoromethylhypoxanthine was obtained (0.026 g, yield:
13%) by column chromatography.
1H-NMR (deuterated dimethyl sulfoxide): δ8.13(s, 1H),
12.52(s, 1H), 14.89(brs, 1H).
13C-NMR (deuterated dimethyl sulfoxide): 5119.0(q,
JCF=270.1Hz) , 122.6, 138. 0 (q, JCF=41.2Hz), 147.6, 152.3,
156.4.
19F-NMR (deuterated dimethyl sulfoxide): 5-63.2.
MS (m/z): 205[M+H]+.
EXAMPLE 37


0.19 g (1.0 mmol) of xanthine was weighed and placed in a 100 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 47 ml of
dimethyl sulfoxide, 2.0 ml of a in dimethyl sulfoxide
solution of sulfuric acid, 1.0 ml of a 3.0 mol/l of
dimethyl sulfoxide solution of trifluoromethyl iodide,
0.2 ml of a 30% hydrogen peroxide aqueous solution and
0.3 ml of a 1.0 mol/l aqueous solution of ferric sulfate.
The mixture was stirred at 40 to 50°C for 20 minutes and
then the resulting solution was cooled to room
temperature. Formation of 8-trifluoromethylxanthine (19F-
NMR yield: 44%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 8-
Trifluoromethylxanthine was obtained (0.044 g, yield:
2 0%) by column chromatography.
1H-NMR (deuterated dimethyl sulfoxide) : δ11.16 (s, 1H) ,
11.83(s, 1H), 15.07(brs, 1H).
13C-NMR (deuterated dimethyl sulfoxide): δ110.0, 118.7(q,
JCF=269.9Hz) , 138. 0 (q, JCF=41.1Hz), 148.1, 151.7, 156.2.
19F-NMR (deuterated dimethyl sulfoxide): δ-63.1.
MS (m/z) : 221 [M+H]+.
EXAMPLE 38


0.19 g (1.0 mmol) of caffeine was weighed and placed in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 2.0 ml of
dimethyl sulfoxide, 2.0 ml of a in dimethyl sulfoxide
solution of sulfuric acid, 1.0 ml of a 3.0 mol/l of
dimethyl sulfoxide solution of trifluoromethyl iodide,
0.3 ml of a 1.0 mol/l aqueous solution of ferric sulfate
and 0.2 ml of a 30% hydrogen peroxide aqueous solution.
The mixture was stirred at 40 to 50°C for 20 minutes and
then the resulting solution was cooled to room
temperature. Formation of 8-trifluoromethylcaffeine (19F-
NMR yield: 17%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard. 8-
Trifluoromethylcaffeine was obtained as a white solid
(0.033 g, yield: 13%) by column chromatography.
1H-NMR (deuterated acetone): δ3.33(s, 3H), 3.52(s, 3H),
4.21(q, JHF=1.25Hz, 3H).
13C-NMR (deuterated acetone): δ27.8, 29.7, 33.3(q,
JCF=1.98Hz), 110.3, 119. 2 (q, JCF=270 . 2Hz) , 138. 4 (q,
JCF=39.6Hz) , 147.0.
19F-NMR (deuterated acetone) : δ-62.1 (d, JHF=1.25Hz)
MS (m/z): 262[M]+.
EXAMPLE 39
Formation of 8-trifluoromethylcaffeine (19F-NMR
yield: 48%) was confirmed in the same manner as in
Example 38, except that 0.5 ml of a in dimethyl sulfoxide

solution of sulfuric acid was used instead of 2.0 ml of
the in dimethyl sulfoxide solution of sulfuric acid.
EXAMPLE 40
1.94 g (10 mmol)of caffeine was weighed and placed
in a 100 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 20 ml of
dimethyl sulfoxide, 2 0 ml of a in dimethyl sulfoxide
solution of sulfuric acid, 10 ml of a 3.0 mol/l dimethyl
sulfoxide solution of trifluoromethyl iodide, 3.0 ml of a
1.0 mol/l aqueous solution of ferric sulfate and 2.0 ml
of a 30% hydrogen peroxide aqueous solution. The mixture
was stirred at 50 to 60°C for 60 minutes and then the
resulting solution was cooled to room temperature.
Formation of 8-trifluoromethylcaffeine (19F-NMR yield:
20%) was confirmed by 19F-NMR with 2,2,2-trifluoroethanol
as an internal standard.
EXAMPLE 41
1.94 g (10 mmol) of caffeine was weighed and placed
in a 300 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 50 ml of
dimethyl sulfoxide, 0.055 ml of concentrated sulfuric
acid, 30 mmol of gaseous trifluoromethyl iodide, 3.0 ml
of a 1.0 mol/l aqueous solution of ferric sulfate and 2.0
ml of a 3 0% hydrogen peroxide aqueous solution. The
mixture was stirred at 50 to 60°C for 60 minutes and then

the resulting solution was cooled to room temperature.
Formation of 8-trifluoromethylcaffeine (19F-NMR yield:
23%) was confirmed by 19F-NMR with 2,2,2-trifluoroethanol
as an internal standard.
EXAMPLE 42
Formation of 8-trifluoromethylcaffeine (19F-NMR
yield: 15%) was confirmed in the same manner as in
Example 41, except that a 1.0 mol/l aqueous solution of
ammonium ferric sulfate was used instead of the 1.0 mol/l
aqueous solution of ferric sulfate.
EXAMPLE 43
0.19 g (1.0 mmol) of caffeine was weighed and placed
in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 0.21 ml of
a 42% tetrafluoroboric acid aqueous solution, 4.0 ml of
dimethyl sulfoxide, 1.0 ml of a 3.0 mol/l dimethyl
sulfoxide solution of trifluoromethyl iodide, 0.3 ml of a
1.0 mol/l aqueous solution of ferric tetrafluoroborate
and 0.2 ml of a 30% hydrogen peroxide aqueous solution.
The mixture was stirred at 40 to 50°C for 20 minutes and
then the resulting solution was cooled to room
temperature. Formation of 8-trifluoromethylcaffeine (19F-
NMR yield: 11%) was confirmed by 19F-NMR with 2,2,2-
trifluoroethanol as an internal standard.
EXAMPLE 44
0.19 g (1.0 mmol) of caffeine was weighed and placed

in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 0.016 g
(0.3 mmol) of iron powder, 2.0 ml of dimethyl sulfoxide,
2.0 ml of a in dimethyl sulfoxide solution of sulfuric
acid, 1.0 ml of a 3.0 mol/l dimethyl sulfoxide solution
of trifluoromethyl iodide and 0.2 ml of a 30% hydrogen
peroxide aqueous solution. The mixture was stirred at 4 0
to 50°C for 20 minutes and then the resulting solution
was cooled to room temperature. Formation of 8-
trifluoromethylcaffeine (19F-NMR yield: 37%) was
confirmed by 19F-NMR with 2,2,2-trifluoroethanol as an
internal standard.
EXAMPLE 45
0.19 g (1.0 mmol) of caffeine and 0.056 g (0.3 mmol)
of ferrocene were weighed and placed in a 50 ml two-neck
flask equipped with a magnetic rotor and the atmosphere in the flask was replaced with argon. The following
materials were added thereinto: 2.0 ml of dimethyl
sulfoxide, 2.0 ml of a in dimethyl sulfoxide solution of
sulfuric acid, 1.0 ml of a 3.0 mol/l of dimethyl
sulfoxide solution of trifluoromethyl iodide, 0.3 ml of a
1.0 mol/l aqueous solution of ferric sulfate and 0.2 ml
of a hydrogen peroxide aqueous solution. The mixture was
stirred at 40 to 50°C for 20 minutes and then the
resulting solution was cooled to room temperature.
Formation of 8-trifluoromethylcaffeine (19F-NMR yield:

17%) was confirmed by 19F-NMR with 2,2,2-trifluoroethanol
as an internal standard.
EXAMPLE 46
Formation of 8-trifluoromethylcaffeine (19F-NMR
yield: 13%) was confirmed in the same manner as in
Example 41 except that the reaction was carried out in
the atmosphere of air without the replacement with argon.
EXAMPLE 47

0.18 g (1.0 mmol) of caffeine was weighed and placed in a 50 ml two-neck flask equipped with a magnetic rotor
and the atmosphere in the flask was replaced with argon.
The following materials were added thereinto: 3.0 ml of
dimethyl sulfoxide, 2.0 ml of a in dimethyl sulfoxide
solution of sulfuric acid, 1.3 ml of tridecafluoro-1-
iodohexane, 0.3 ml of a 1.0 mol/l aqueous solution of
ferric sulfate and 0.2 ml of a 30% hydrogen peroxide
aqueous solution. The mixture was stirred at 40 to 50°C
for 2 0 minutes and then the resulting solution was cooled
to room temperature. Formation of 8-
perfluorohexylcaffeine (19F-NMR yield: 30%) was confirmed
by 19F-NMR with 2,2,2-trifluoroethanol as an internal
standard. 8-Perfluorohexylcaffeine was obtained as a
white solid (0.077 g, yield: 15%) by column

chromatography.
1H-NMR (deuterated acetone): δ3.33(s, 3H) , 3.52 (s, 3H) ,
4.21 (s, 3H).
19F-NMR (deuterated acetone): δ-125.9(m, 2F), -122.8(s,
2F) , -122.0(m, 2F) , -114.2(m, 4F) , -80.5(q, JFF=9.4Hz,
3F).
MS (m/z) : 513[M+H]+ .
EXAMPLE 48

0.18 g (1.0 mmol) of theobromine was weighed and
placed in a 50 ml two-neck flask equipped with a magnetic
rotor and the atmosphere in the flask was replaced with
argon. The following materials were added thereinto: 17
ml of dimethyl sulfoxide, 2.0 ml of a in dimethyl
sulfoxide solution of sulfuric acid, 1.0 ml of a 3.0
mol/l dimethyl sulfoxide solution of trifluoromethyl
iodide, 0.3 ml of a 1.0 mol/l aqueous solution of ferric
sulfate and 0.2 ml of a 30% hydrogen peroxide aqueous
solution. The mixture was stirred at 40 to 50°C for 20
minutes and then the resulting solution was cooled to
room temperature. Formation of 8-
trifluoromethyltheobromine (19F-NMR yield: 12%) was
confirmed by 19F-NMR with 2,2,2-trifluoroethanol as an
internal standard. 8-Trifluoromethyltheobromine was

obtained as a white solid (0.024 g, yield: 10%) by column
chromatography.
1H-NMR (deuterated dimethyl sulfoxide) : δ3.34(s, 3H),
4.04(s, J=1.7Hz, 3H), 11.48(brs, 1H).
13C-NMR (deuterated dimethyl sulfoxide): δ33.1(q,
JCF=1.9Hz), 42.1, 109.9(q, JCF=l-9Hz), 118.2 (q,
JCF=270.7Hz) , 137.0 (q, JCF=39.2Hz), 147.5, 150.6, 155.2.
19F-NMR (deuterated dimethyl sulfoxide): δ-61.6.
MS (m/z) : 248[M]+.
EXAMPLE 49

0.18 g (1.0 mmol) of theophylline was weighed and
placed in a 50 ml two-neck flask equipped with a magnetic
rotor and the atmosphere in the flask was replaced with
argon. The following materials were added thereinto: 2.0
ml of dimethyl sulfoxide, 2.0 ml of a in dimethyl
sulfoxide solution of sulfuric acid, 1.0 ml of a 3.0
mol/l dimethyl sulfoxide solution of trifluoromethyl
iodide, 0.2 ml of a 3 0% hydrogen peroxide aqueous
solution and 0.3 ml of a 1.0 mol/l aqueous solution of
ferric sulfate. The mixture was stirred at 40 to 50°C
for 20 minutes and then the resulting solution was cooled
to room temperature. Formation of 8-
trifluoromethyltheophylline (19F-NMR yield: 48%) was

confirmed by 19F-NMR with 2,2,2-trifluoroethanol as an
internal standard. 8-Trifluoromethyltheophylline was
obtained as a white solid (0.086 g, yield: 35%) by column
chromatography.
1H-NMR (deuterated dimethyl sulfoxide) : δ3.24 (s, 3H),
3.42 (s, 3H) , 15.2(brs, 1H) .
13C-NMR (deuterated dimethyl sulfoxide): 527.9, 29.9,
109.1, 118.2 (q, JCF=270.0Hz) , 137.3 (q, JCF=37.2Hz), 146.8,
150.9, 154.6.
19F-NMR (deuterated dimethyl sulfoxide): δ-62.3.
MS (m/z) : 248[M]+.
EXAMPLE 50

0.18 g (1.0 mmol) of theophylline was weighed and
placed in a 50 ml two-neck flask equipped with a magnetic
rotor and the atmosphere in the flask was replaced with
argon. The following materials were added thereinto: 3.0
ml of dimethyl sulfoxide, 2.0 ml of a in dimethyl
sulfoxide solution of sulfuric acid, 1.3 ml of
tridecafluoro-1-iodohexane, 0.3 ml of a 1.0 mol/l aqueous
solution of ferric sulfate and 0.2 ml of a 3 0% hydrogen
peroxide aqueous solution. The mixture was stirred at 40
to 50°C for 20 minutes and then the resulting solution
was cooled to room temperature. Formation of 8-

perfluorohexyltheophylline (19F-NMR yield: 12%) was
confirmed by 19F-NMR with 2,2,2-trifluoroethanol as an
internal standard. 8-Perfluorohexyltheophylline was
obtained as a white solid (0.02 g, yield: 4.0%) by column
chromatography.
1H-NMR (deuterated acetone): δ3.34(s, 3H), 3.57(s, 3H),
14.2(brs, 1H).
19F-NMR (deuterated acetone): δ-127.0(m, 2F), -123.6(brs,
2F), -122.9(m, 2F), -122.4(brs, 2F), -112.3(m, 2F),
-81.9(t, JFF=7.1Hz, 3F) .
MS (m/z) : 499[M+H]+.
EXAMPLE 51

Formation of 6-(2-chloroethyl)-5-
trifluoromethyluracil (19F-NMR yield: 55%) was confirmed in the same manner as in Example 22, except that 0.16 g
of 6-(2-chloroethyl)uracil was used instead of 0.37 g of
2',3',5'-tri-O-acetyluridine. Then 6-(2-chloroethyl)-5-
trifluoromethyluracil was obtained as a white solid (0.10
g, yield: 45%) by preparative thin-layer chromatography.
INDUSTRIAL APPLICABILITY
The nucleobase having a perfluoroalkyl group
according to the present invention is useful as a medical

drug, an intermediate for preparing medical and
agricultural chemicals, and so on.
The entire disclosure of Japanese Patent Application
No. 2005-324943 filed on November 9, 2005 including the
specification, claims, and summary is incorporated herein
by reference in its entirety.

CLAIMS:
1. A process for producing a nucleobase having a
perfluoroalkyl group, the process comprising: carrying
out a reaction of a nucleobase with a perfluoroalkyl
halide represented by the general formula (2):

wherein Rf is a C1-C6 perfluoroalkyl group and X is a
halogen atom, in the presence of a sulfoxide represented
by the general formula (1):

wherein each of Rla and Rlb is a C1-C12 alkyl group or an
optionally substituted phenyl group, a peroxide and an
iron compound.
2. The process according to Claim 1, wherein the
reaction is carried out in the presence of an acid.
3. The process according to Claim 1 or 2, wherein the
nucleobase are uracils represented by the general formula
(3) :

wherein R2 is a hydrogen atom, an optionally substituted

C1-C6 alkyl group or a protecting group for nitrogen, R3
is a hydrogen atom, an optionally substituted C1-C6 alkyl
group, a protecting group for nitrogen, or one of pentose
residues and analogs thereof, and R4 is a hydrogen atom,
an optionally substituted C1-C6 alkyl group, an
optionally substituted C1-C4 alkoxy group, an optionally
substituted amino group, a carboxy group, an optionally
substituted carbamoyl group, or an optionally substituted
C2-C5 alkoxycarbonyl group; cytosines represented by the
general formula (4):

wherein R5 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group, a protecting group for nitrogen, or
one of pentose residues and analogs thereof, R6 is a
hydrogen atom, an optionally substituted C1-C6 alkyl
group, an optionally substituted amino group, a carboxy
group, an optionally substituted carbamoyl group, or an
optionally substituted C2-C5 alkoxycarbonyl group, and
each of R7 and R8 is a hydrogen atom or a protecting
group for nitrogen; adenines represented by the general
formula (5):


wherein R9 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group, a protecting group for nitrogen, or
one of pentose residues and analogs thereof, R10 is a
hydrogen atom, an optionally substituted C1-C6 alkyl
group, an optionally substituted amino group, a carboxy
group, an optionally substituted carbamoyl group, or an
optionally substituted C2-C5 alkoxycarbonyl group, and
each of R11 and R12 is a hydrogen atom or a protecting
group for nitrogen; guanines represented by the general
formula (6):

wherein R13 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group or a protecting group for nitrogen, R14
is a hydrogen atom, an optionally substituted C1-C6 alkyl
group, a protecting group for nitrogen, or one of pentose
residues and analogs thereof, and each of R15 and R16 is a

hydrogen atom or a protecting group for nitrogen;
hypoxanthines represented by the general formula (7):

wherein R17 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group or a protecting group for nitrogen, and
R18 is a hydrogen atom, an optionally substituted C1-C6
alkyl group, a protecting group for nitrogen, or one of
pentose residues and analogs thereof; or xanthines
represented by the general formula (8):

wherein R19 is a hydrogen atom, an optionally substituted
C1-C6 alkyl group or a protecting group for nitrogen, R20
is a hydrogen atom, an optionally substituted C1-C6 alkyl
group, a protecting group for nitrogen, or one of pentose
residues and analogs thereof, and R21 is a hydrogen atom,
an optionally substituted C1-C6 alkyl group or a
protecting group for nitrogen.
4. The process according to Claim 3, wherein the
nucleobase are uracils represented by the general formula

(3) :

wherein R2, R3 and R4 are the same as those defined above.
5. The process according to any one of Claims 1 to 4,
wherein X is iodine or bromine.
6. The process according to any one of Claims 1 to 5,
wherein Rf is a trifluoromethyl group or a perfluoroethyl
group.
7. The process according to any one of Claims 1 to 6,
wherein the iron compound is ferric sulfate, ammonium
ferric sulfate, ferric tetrafluoroborate, ferric chloride,
ferric bromide, ferric iodide, ferric acetate, ferric
oxalate, bis(acetylacetonato)iron(II), ferrocene, bis(η5-
pentamethylcyclopentadienyl)iron or an iron powder.
8. The process according to Claim 7, wherein the iron
compound is ferric sulfate, ammonium ferric sulfate,
ferric tetrafluoroborate, ferrocene or an iron powder.
9. The process according to any one of Claims 1 to 8,
wherein the peroxide is hydrogen peroxide, a hydrogen
peroxide-urea composite, tert-butyl peroxide or
peroxyacetic acid.
10. The process according to Claim 9, wherein the
peroxide is hydrogen peroxide or a hydrogen peroxide-urea

composite.
11. The process according to any one of Claims 2 to 10,
wherein the acid is sulfuric acid, hydrochloric acid,
hydrogen bromide, hydrogen iodide, nitric acid,
phosphoric acid, hexafluorophosphoric acid,
tetrafluoroboric acid, formic acid, acetic acid,
propionic acid, oxalic acid, p-toluenesulfonic acid,
trifluoromethanesulfonic acid or trifluoroacetic acid.
12. The process according to Claim 11, wherein the acid
is sulfuric acid, tetrafluoroboric acid or
trifluoromethanesulfonic acid.
13. The process according to any one of Claims 1 to 12,
wherein each of Rla and Rlb is a methyl group, a butyl
group or a phenyl group.
14. The process according to any one of Claims 1 to 13,
wherein a temperature of the reaction is from 20 to 100°C.
15. The process according to any one of Claims 1 to 14,
wherein a pressure of the reaction is from the
atmospheric pressure (0.1 MPa) to 1.0 MPa.
16. 5-Perfluoroalkyluracils represented by the general
formula (9):

wherein Rf is a C1-C6 perfluoroalkyl group, each of R22

and R23 is a hydrogen atom or an optionally substituted
C1-C6 alkyl group, and R24 is an optionally substituted
C1-C6 alkyl group, an optionally substituted amino group
or an optionally substituted C2-C5 alkoxycarbonyl group,
provided that in a case where each of R22 and R23 is a
hydrogen atom, R24 is an optionally substituted C2-C5
alkoxycarbonyl group.
17. 8-Perfluoroalkylxanthines represented by the general
formula (10) :

wherein Rf is a C1-C6 perfluoroalkyl group, and each of
R25, R26 and R27 is a hydrogen atom or an optionally
substituted C1-C6 alkyl group, provided that R25, R26 and
R27 are not a hydrogen atom all together.

Provided is a simple and efficient production
process of a nucleobase having a perfluoroalkyl group. A nucleobase (for example, uracils, cytosines, adenines, guanines, hypoxanthines, xanthines, or the like) is reacted with a perfluoroalkyl halide in the presence of a sulfoxide, a peroxide and an iron compound
to produce a perfluoroalkyl-substituted nucleobase, which is useful as an intermediate for medical drugs, economically.

Documents:

01537-kolnp-2008-abstract.pdf

01537-kolnp-2008-claims.pdf

01537-kolnp-2008-correspondence others.pdf

01537-kolnp-2008-description complete.pdf

01537-kolnp-2008-form 1.pdf

01537-kolnp-2008-form 3.pdf

01537-kolnp-2008-form 5.pdf

01537-kolnp-2008-international publication.pdf

01537-kolnp-2008-international search report.pdf

01537-kolnp-2008-pct priority document notification.pdf

01537-kolnp-2008-pct request form.pdf

1537-KOLNP-2008-(08-11-2013)-CORRESPONDENCE.pdf

1537-KOLNP-2008-(10-05-2013)-AMANDED PAGES.pdf

1537-KOLNP-2008-(10-05-2013)-CORRESPONDENCE.pdf

1537-KOLNP-2008-(10-05-2013)-FORM 13.pdf

1537-KOLNP-2008-(10-05-2013)-FORM 2.pdf

1537-KOLNP-2008-(10-05-2013)-FORM 3.pdf

1537-KOLNP-2008-(10-05-2013)-OTHERS.pdf

1537-KOLNP-2008-(10-05-2013)-PETITION UNDER RULR 137-1.1.pdf

1537-KOLNP-2008-(10-05-2013)-PETITION UNDER RULR 137.pdf

1537-KOLNP-2008-(20-11-2013)-CORRESPONDENCE.pdf

1537-KOLNP-2008-(27-11-2013)-AMANDED CLAIMS.pdf

1537-KOLNP-2008-(27-11-2013)-CORRESPONDENCE.pdf

1537-KOLNP-2008-(30-09-2013)CORRESPONDENCE.pdf

1537-KOLNP-2008-ASSIGNMENT-1.1.pdf

1537-KOLNP-2008-ASSIGNMENT.pdf

1537-KOLNP-2008-CORRESPONDENCE 1.1.pdf

1537-KOLNP-2008-CORRESPONDENCE 1.2.pdf

1537-KOLNP-2008-CORRESPONDENCE.pdf

1537-KOLNP-2008-EXAMINATION REPORT.pdf

1537-KOLNP-2008-FORM 13-1.1.pdf

1537-KOLNP-2008-FORM 13.pdf

1537-KOLNP-2008-FORM 18.pdf

1537-KOLNP-2008-FORM 3.1.pdf

1537-KOLNP-2008-GRANTED-ABSTRACT.pdf

1537-KOLNP-2008-GRANTED-CLAIMS.pdf

1537-KOLNP-2008-GRANTED-DESCRIPTION (COMPLETE).pdf

1537-KOLNP-2008-GRANTED-FORM 1.pdf

1537-KOLNP-2008-GRANTED-FORM 2.pdf

1537-KOLNP-2008-GRANTED-FORM 3.pdf

1537-KOLNP-2008-GRANTED-FORM 5.pdf

1537-KOLNP-2008-GRANTED-SPECIFICATION-COMPLETE.pdf

1537-KOLNP-2008-INTERNATIONAL PUBLICATION.pdf

1537-KOLNP-2008-INTERNATIONAL SEARCH REPORT & OTHERS.pdf

1537-KOLNP-2008-OTHERS.pdf

1537-KOLNP-2008-PA-1.1.pdf

1537-KOLNP-2008-PA.pdf

1537-KOLNP-2008-PETITION UNDER RULE 137.pdf

1537-KOLNP-2008-REPLY TO EXAMINATION REPORT.pdf

1537-KOLNP-2008-TRANSLATED COPY OF PRIORITY DOCUMENT.pdf

1537-KOLNP-2008-WRITEN NOTE OF ARGUMENT.pdf


Patent Number 258337
Indian Patent Application Number 1537/KOLNP/2008
PG Journal Number 01/2014
Publication Date 03-Jan-2014
Grant Date 01-Jan-2014
Date of Filing 16-Apr-2008
Name of Patentee TOSOH CORPORATION
Applicant Address 4560, KAISEI-CHO, SHUNAN-SHI, YAMAGUCHI
Inventors:
# Inventor's Name Inventor's Address
1 YAMAKAWA TETSU 5-11-18, SHINMACHI, NISHITOKYO-SHI, TOKYO 2020023
2 URAGUCHI DAI SUKE 3-252-5-305, SHINONOKAZE, MIDORI-KU, NAGOYA-SHI, AICHI 4580015
3 TOKUHISA KENJI 4-6-6, MADOKORO, SHUNAN-SHI,, YAMAGUCHI 7460012
4 YAMAMOTO KYOKO 2-12-40-201, SAKAE-CHO, ODAWARA-SHI, KANAGAWA 2500011
PCT International Classification Number C07D 239/54
PCT International Application Number PCT/JP2006/322094
PCT International Filing date 2006-11-06
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 2005-324943 2005-11-09 Japan